[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 153
1. Ilias EJ, Malheiros CA, Kassab P, Castro OA: [Simulation of D1 lymphadenectomy in patients submitted to D2 lymphadenectomy. Prospective study of 57 patients with gastric adenocarcinoma]. Rev Assoc Med Bras (1992); 2006 Jul-Aug;52(4):270-2
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Simulation of D1 lymphadenectomy in patients submitted to D2 lymphadenectomy. Prospective study of 57 patients with gastric adenocarcinoma].
  • [Transliterated title] Linfadenectomia no adenocarcinoma gástrico.
  • BACKGROUND: To simulate a D1 lymphadenectomy in 57 patients who had already been submitted to D2 lymphadenectomy, and analyze stage migration using the Japanese Gastric Cancer Association (JGCA) staging system.
  • All patients were re-staged based on the new data, in order to evaluate the stage migration according to the JGCA staging system.
  • In IA, IB and II tumors, there were no changes in the stage after simulation of D1 lymphadenectomy.
  • In ten IIIA tumors, three migrated to stage II and IB; in 21 tumors staged as IIIB, a migration was observed in 18; all stage IV tumors migrated to IIIB after the D1 simulation.
  • CONCLUSION: a) D2 lymphadenectomy is important for the correct staging of gastric cancer;.
  • b) simulation of D1 lymphadenectomy changed the stage of advanced tumors, particularly in stages IIIA, IIIB, and IV;.
  • [MeSH-major] Adenocarcinoma. Gastrectomy. Lymph Node Excision / methods. Stomach Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16967148.001).
  • [ISSN] 0104-4230
  • [Journal-full-title] Revista da Associação Médica Brasileira (1992)
  • [ISO-abbreviation] Rev Assoc Med Bras (1992)
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


2. Koufuji K, Shirouzu K, Aoyagi K, Yano S, Miyagi M, Imaizumi T, Takeda J: Surgery and clinicopathological features of gastric adenocarcinoma involving the esophago-gastric junction. Kurume Med J; 2005;52(3):73-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery and clinicopathological features of gastric adenocarcinoma involving the esophago-gastric junction.
  • To clarify the optimal operative procedure for gastric adenocarcinoma involving the esophago-gastric junction (EGJ), we investigated 49 cases with an upper gastric cancer invading the esophagus who underwent surgical treatment in our department during the period from 1991 to 2000.
  • According to Siewert's classification, there were 21 cases with a type II tumor, and 28 cases with a type III tumor.
  • Proximal gastrectomy was performed in 6 cases at the early stage and in 10 cases at the advanced stage with distant metastasis (M1).
  • Total gastrectomy was done in 33 cases at the advanced stage, and 3 of these 33 cases had metastasis to the parapyloric lymph nodes.
  • Tumors were stage I in 8 cases, II in 5 cases, III in 13 cases and IV in 23 cases, and the curability was categorized as A in 8 cases, B in 20 and C in 21.
  • The overall 5-year-survival rate was 25%, and the rates according to cancer stage were 86% for stage I, 40% for stage II , 21% for stage III and 0% for stage IV.
  • The 5-year survival rates of cases at stage II and III were 33% for cases using the left thoraco-abdominal approach and 28% for cases with the abdominal approach.
  • Based on these results, we recommend distal esophagectomy with total gastrectomy, and occasional combined resection of the spleen and the diaphragm through a left thoraco-abdominal approach for advanced gastric adenocarcinoma involving the EGJ.
  • [MeSH-major] Adenocarcinoma / surgery. Esophageal Neoplasms / surgery. Esophagogastric Junction. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16422172.001).
  • [ISSN] 0023-5679
  • [Journal-full-title] The Kurume medical journal
  • [ISO-abbreviation] Kurume Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


3. Zhao P, Liu W, Lu YL: Clinicopathological significance of FHIT protein expression in gastric adenocarcinoma patients. World J Gastroenterol; 2005 Sep 28;11(36):5735-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological significance of FHIT protein expression in gastric adenocarcinoma patients.
  • AIM: To investigate the expression of fragile histidine triad (FHIT) protein, and the possible relationship between FHIT expression and clinicopathological indices in gastric carcinoma.
  • METHODS: FHIT protein expression was examined in 76 cases of gastric carcinoma, 58 cases of intraepithelial neoplasia, and 76 cases of corresponding normal mucosae by immunohistochemical method to analyze its relationship to histological grade, clinical stage, metastatic status and prognosis.
  • RESULTS: The FHIT protein expression was positive in 28/76 (36.8%) cases of adenocarcinoma tissue, 22/58 (37.9%) cases of adjacent dysplastic tissue and 76/76 (100%) cases of distal normal gastric mucosa.
  • There was a significant difference in the expression of FHIT protein between cancer or adjacent intraepithelial neoplasia and normal gastric mucosa (P = 0.000).
  • FHIT protein expression was found in 64.3% (18/28) of grades I and II cancers, and 20.8% (10/48) of grade III cancers (P = 0.000), in 56.3% (18/32) of stages I and II cancers and 22.7% (10/44) of stages III and IV cancers (P = 0.004), and in 63.6% (14/22) of cancers without metastasis but only 25.9% (14/54) of those with metastasis (P = 0.003).
  • The significant difference in the expression of FHIT was found between histological grade, clinical stage and metastatic status of cancer.
  • Loss of FHIT protein expression may be associated with carcinogenesis, invasion, metastasis and prognosis of gastric adenocarcinoma.
  • [MeSH-major] Acid Anhydride Hydrolases / metabolism. Adenocarcinoma / metabolism. Gene Expression Regulation, Neoplastic. Neoplasm Proteins / metabolism. Stomach Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16237777.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / fragile histidine triad protein; EC 3.6.- / Acid Anhydride Hydrolases
  • [Other-IDs] NLM/ PMC4481500
  •  go-up   go-down


Advertisement
4. Guo W, Dong Z, Guo Y, Kuang G, Yang Z, Chen Z: Detection of promoter hypermethylation of the CpG island of E-cadherin in gastric cardiac adenocarcinoma. Eur J Med Res; 2009 Sep 28;14(10):453-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of promoter hypermethylation of the CpG island of E-cadherin in gastric cardiac adenocarcinoma.
  • The aim of this study was to investigate the promoter methylation and expression of E-cadherin gene in gastric cardiac adenocarcinoma (GCA).
  • Methylation frequencies of stage III and IV tumor tissues was significantly higher than that in stage I and II tumor tissues (P = 0.01).
  • Positive immunostaining of stage III and IV tumor tissues was significantly lower than stage I and II tumor tissues (P<0.01).
  • CONCLUSIONS: High methylation status of the 5' CpG island of E-cadherin gene may be one of the mechanisms in the development of gastric cardiac adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Cadherins / genetics. Cardia. CpG Islands. DNA Methylation. Promoter Regions, Genetic. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] Hum Mutat. 1998;12(4):226-37 [9744472.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15339-44 [9860970.001]
  • [Cites] Oncogene. 1999 Jan 28;18(4):869-76 [10023662.001]
  • [Cites] Hum Mol Genet. 1999 Apr;8(4):607-10 [10072428.001]
  • [Cites] Lancet. 1999 Jul 31;354(9176):356-7 [10437861.001]
  • [Cites] Int J Cancer. 1999 Nov 26;83(5):620-4 [10521797.001]
  • [Cites] Cancer Res. 1998 Sep 15;58(18):4086-9 [9751616.001]
  • [Cites] J Nutr. 2000 Feb;130(2S Suppl):338S-339S [10721901.001]
  • [Cites] Nat Genet. 2000 Jul;25(3):269-77 [10888872.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2765-9 [11555590.001]
  • [Cites] Science. 2001 Dec 7;294(5549):2113-5 [11739943.001]
  • [Cites] Gut. 2003 Apr;52(4):502-6 [12631658.001]
  • [Cites] Expert Rev Mol Med. 2002 Mar;4(4):1-17 [14987388.001]
  • [Cites] Adv Cancer Res. 1990;54:1-23 [2404377.001]
  • [Cites] Curr Opin Cell Biol. 1993 Oct;5(5):797-805 [8240823.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3845-52 [8033105.001]
  • [Cites] Br J Cancer. 1995 Feb;71(2):376-9 [7841055.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7416-9 [7543680.001]
  • [Cites] Cancer Res. 1995 Nov 15;55(22):5195-9 [7585573.001]
  • [Cites] Curr Opin Cell Biol. 1995 Oct;7(5):619-27 [8573335.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Int J Cancer. 1997 May 2;71(3):355-9 [9139867.001]
  • [Cites] Br J Cancer. 1997;75(9):1389-96 [9155065.001]
  • [Cites] Adv Cancer Res. 1998;72:141-96 [9338076.001]
  • [Cites] Cancer Res. 1998 May 15;58(10):2063-6 [9605742.001]
  • [Cites] Am J Pathol. 1998 Aug;153(2):333-9 [9708792.001]
  • [Cites] Gastroenterology. 1998 Dec;115(6):1381-6 [9834265.001]
  • (PMID = 19748854.001).
  • [ISSN] 0949-2321
  • [Journal-full-title] European journal of medical research
  • [ISO-abbreviation] Eur. J. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cadherins; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC3352230
  •  go-up   go-down


5. Falk S, Anthoney A, Eatock M, Van Cutsem E, Chick J, Glen H, Valle JW, Drolet DW, Albert D, Ferry D, Ajani J: Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma. Br J Cancer; 2006 Aug 21;95(4):450-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma.
  • A two-stage Simon design was used to evaluate the response rate of OSI-7904L, a liposome encapsulated thymidylate synthase inhibitor, in advanced gastric and/or gastroesophageal adenocarcinoma (A-G/GEJA), administered intravenously at 12 mg m(-2) over 30 min every 21 days.
  • [MeSH-minor] Adenocarcinoma. Adult. Aged. Aged, 80 and over. Antineoplastic Agents. Female. Humans. Isoindoles. Male. Middle Aged. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2001 Jul;7(7):1901-11 [11448903.001]
  • [Cites] Int J Oncol. 2000 Oct;17(4):653-8 [10995874.001]
  • [Cites] Int J Colorectal Dis. 2002 Jan;17(1):46-9 [12018454.001]
  • [Cites] Ann Oncol. 2002;13 Suppl 4:13-22 [12401661.001]
  • [Cites] Mol Cancer Ther. 2002 May;1(7):545-52 [12479273.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):815-9 [12610179.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):6004-7 [14522928.001]
  • [Cites] J Pharmacol Exp Ther. 2004 Jun;309(3):894-902 [14982966.001]
  • [Cites] Methods Mol Biol. 2004;281:91-103 [15220523.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] Clin Chem. 1993 Feb;39(2):263-71 [8432015.001]
  • [Cites] Cancer Res. 1995 Apr 1;55(7):1407-12 [7882343.001]
  • [Cites] Cell Struct Funct. 1995 Jun;20(3):191-7 [7586009.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):176-82 [8558194.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):261-7 [8996151.001]
  • [Cites] Ann Oncol. 1997 Feb;8(2):163-8 [9093725.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5487-95 [16061865.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6957-65 [16145066.001]
  • [Cites] Br J Cancer. 2006 Jan 30;94(2):203-7 [16333305.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2898-904 [12782596.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12810-5 [10536004.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(14):2648-57 [10894863.001]
  • [Cites] J Exp Clin Cancer Res. 2000 Jun;19(2):189-95 [10965817.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):1996-2004 [11956258.001]
  • (PMID = 16880795.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ((S)-2-(5-(1,2-dihydro-3-methyl-1-oxobenzo(f)-quinazoline-9-yl)methyl)amino-1-oxo-2-isoindolynyl)-glutaric acid; 0 / Antineoplastic Agents; 0 / Glutarates; 0 / Isoindoles; 0 / Quinazolines
  • [Other-IDs] NLM/ PMC2360664
  •  go-up   go-down


6. Necula A, Vlad L, Iancu C, Munteanu D, Puia C, Bălă O, AlHajaar N, Pop F, Radu H, Osian G, Graur F, Furcea L, Stanca M, Molnar G, Mocanu L: [Morbidity and mortality in gastric cancer surgery--analysis of 468 cases with gastric adenocarcinoma]. Chirurgia (Bucur); 2008 Sep-Oct;103(5):529-37
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Morbidity and mortality in gastric cancer surgery--analysis of 468 cases with gastric adenocarcinoma].
  • [Transliterated title] Morbiditate şi mortalitate în chirurgia cancerului gastric--analiza a 468 cazuri de adenocarcinom gastric.
  • The aim of this study is to evaluate the morbidity and mortality in the surgical treatment of gastric cancer and the factors that could influencing them.
  • We made a retrospective analysis of a group of 468 patients with gastric adenocarcinoma which have been operated in the 3RD Surgical Clinic-Cluj Napoca--01.01.1998-31.12.2003.
  • We analyzed parameters related to patient, pTNM stage and type of treatment.
  • Morbidity was significantly higher in these circumstances: elder patients, cases with lower serum levels of hemoglobin and total proteins, after Billroth II procedures; we found no significant differences of morbidity depending on gender, pTNM stage, type of intervention: simple or multiorgan resection, subtotal or total gastrectomy, radical or palliative procedure or only exploratory laparotomy, presence or absence of splenectomy or caudal pancreatectomy, D1 or D2 lymphadenectomy (in radical procedures), palliative resection or gastrojejunal bypass.
  • Elder patients and male patients have had a mortality significantly higher; we found no significant differences of mortality depending on serum levels of hemoglobin and total proteins, pTNM stage, type of intervention: simple or multiorgan resection, subtotal or total gastrectomy, radical or palliative procedure or only exploratory laparotomy, presence or absence of splenectomy or caudal pancreatectomy, D1 or D2 lymphadenectomy (in radical procedures), type of restoring of the digestive continuity after subtotal gastrectomy, palliative resection or gastrojejunal bypass.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Gastrectomy. Stomach Neoplasms / mortality. Stomach Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19260628.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


7. Căinap C, Părău A, Muntean A, Hodorog A, Vlad L: [New generation chemotherapy in the treatment of operated gastric cancer--an alternative to traditional chemotherapy]. Chirurgia (Bucur); 2010 Jan-Feb;105(1):31-6
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [New generation chemotherapy in the treatment of operated gastric cancer--an alternative to traditional chemotherapy].
  • [Transliterated title] Chimioterapia de generaţie nouă in cancerul gastric operat--o alternativă la chimioterapia clasică.
  • Gastric cancer remains one of the most difficult tumour type despite his relative reduction of his global incidence, it remains on of the most deadly cancer.
  • The latest advances in therapy of the gastric cancer ameliorate the results in terms of survival.
  • In our prospective, non-randomized study, we enrolled 40 patients with gastric adenocarcinoma stage IB to IV (M0) who were surgically treated, treated with chemoradioterapy, but with chemotherapy modified by ECX (epirubicine, cisplatine, xeloda) which is now considered standard in metastatic setting.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20405677.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] Clinical Trial, Phase II; English Abstract; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 3Z8479ZZ5X / Epirubicin; 6804DJ8Z9U / Capecitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


8. Siewert JR, Stein HJ, Feith M: Adenocarcinoma of the esophago-gastric junction. Scand J Surg; 2006;95(4):260-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the esophago-gastric junction.
  • BACKGROUND: The border between the esophagus and stomach gives rise to many discrepancies in the current literature regarding the etiology, classification and surgical treatment of adenocarcinoma arising at the esophago-gastric junction.
  • We have consequently used the AEG-criteria (adenocarcinoma of the esophago-gastric junction) for classification and have based the selection of the surgical approach on the anatomic topographic subclassification.
  • METHODS: In the following we report an analysis of a large and homogeneously classified population of 1602 consecutive patients with adenocarcinoma of the esophago-gastric junction, with an emphasis on the surgical approach, the pattern of lymphatic spread, the outcome after surgical treatment and the prognostic factors.
  • RESULTS: The study confirms the marked differences in sex distribution, associated specialized intestinal metaplasia in the esophagus, tumor grading, tumor growth pattern, lymphatic spread, and stage between the three tumor entities.
  • CONCLUSION: The classification of adenocarcinomas of the esophago-gastric junction in three types, AEG type I, type II and type III shows marked differences between the tumor entities and is recommended for selection of a proper surgical approach.
  • [MeSH-major] Adenocarcinoma / classification. Adenocarcinoma / surgery. Esophageal Neoplasms / classification. Esophageal Neoplasms / surgery. Esophagogastric Junction. Stomach Neoplasms / classification. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17249275.001).
  • [ISSN] 1457-4969
  • [Journal-full-title] Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society
  • [ISO-abbreviation] Scand J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


9. Park JM, Kim JH, Park SS, Kim SJ, Mok YJ, Kim CS: Prognostic factors and availability of D2 lymph node dissection for the patients with stage II gastric cancer: comparative analysis of subgroups in stage II. World J Surg; 2008 Jun;32(6):1037-44
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors and availability of D2 lymph node dissection for the patients with stage II gastric cancer: comparative analysis of subgroups in stage II.
  • BACKGROUND: According to the fifth edition of the UICC TNM classification, stage II gastric cancer has three subgroups: T1N2M0, T2N1M0, and T3N0M0.
  • This study was designed to investigate the prognosis of stage II gastric cancer according to the T and N category to verify the accuracy of TNM staging for stage II and to determine the prognostic factors for patients with stage II gastric cancer by subgroup.
  • METHODS: Clinicopathologic data from 326 patients with stage II gastric cancer were studied.
  • Univariate survival analysis showed that age, gender, histological type, and the extent of lymph node dissection were significant prognostic factors for stage II gastric cancer.
  • Thus, our data support the accuracy of the TNM staging classification for stage II gastric cancer.
  • However, before recommending limited lymph node dissection for T2N1 stage disease, development of a preoperative method for prediction of depth of invasion and lymph node status is needed.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Lymph Node Excision. Neoplasm Staging. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] World J Surg. 2008 Sep;32(9):2127-8 [18563483.001]
  • [Cites] World J Surg. 1999 May;23(5):492-7; discussion 497-8 [10085399.001]
  • [Cites] Gastric Cancer. 1999 Nov;2(3):173-178 [11957092.001]
  • [Cites] Eur J Cancer. 2001 Sep;37(13):1674-80 [11527695.001]
  • [Cites] J Surg Res. 2002 Apr;103(2):252-9 [11922742.001]
  • [Cites] Surgery. 2000 Feb;127(2):129-35 [10686976.001]
  • [Cites] Surgery. 2002 Jan;131(1 Suppl):S306-11 [11821829.001]
  • [Cites] J Am Coll Surg. 2001 Jan;192(1):25-37 [11192920.001]
  • [Cites] Surgery. 1998 May;123(5):573-8 [9591011.001]
  • [Cites] Gastric Cancer. 2002;5(1):1-5 [12021853.001]
  • [Cites] J Surg Oncol. 2006 Jul 1;94(1):16-20 [16788938.001]
  • [Cites] Eur J Cancer. 1996 Jul;32A(8):1303-9 [8869090.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2069-77 [15082726.001]
  • [Cites] Eur J Cancer. 2000 Feb;36(3):390-6 [10708942.001]
  • [Cites] Br J Surg. 1991 Mar;78(3):334-6 [2021850.001]
  • [Cites] Cancer. 2000 Apr 15;88(8):1763-5 [10760749.001]
  • [Cites] Surg Endosc. 2006 Apr;20(4):559-62 [16446988.001]
  • [Cites] Arch Surg. 2000 Jul;135(7):806-10 [10896374.001]
  • [Cites] World J Gastroenterol. 2005 Dec 21;11(47):7508-11 [16437724.001]
  • [Cites] World J Surg. 1993 May-Jun;17(3):410-4; discussion 415 [8337889.001]
  • [Cites] Ann Surg. 1998 Oct;228(4):449-61 [9790335.001]
  • [Cites] Cancer. 2000 Oct 1;89(7):1418-24 [11013353.001]
  • (PMID = 18347851.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Wilson D, Hiller L, Geh JI: Review of second-line chemotherapy for advanced gastric adenocarcinoma. Clin Oncol (R Coll Radiol); 2005 Apr;17(2):81-90
PubMed Health. DARE review .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Review of second-line chemotherapy for advanced gastric adenocarcinoma.
  • Palliative chemotherapy has been shown to improve survival compared with best supportive care alone in patients with unresectable or recurrent gastric cancer.
  • At this stage, no standard second-line chemotherapy can be offered.
  • We review the published data concerning the use of second-line chemotherapy in gastric adenocarcinoma.
  • Response rates to second-line therapy in phase II trials are similar to those seen for other cancers that are more commonly retreated.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Salvage Therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Clinical Trials, Phase II as Topic. Esophageal Neoplasms / drug therapy. Esophagogastric Junction. Humans. Palliative Care. Survival Analysis

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15830569.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 46
  •  go-up   go-down


11. Friedrich-Rust M, Jaeger C, Gossner L, May A, Günter E, Stolte M, Ell C: [Early duodenal adenocarcinoma arising in gastric metaplasia treated by endoscopic resection]. Z Gastroenterol; 2006 Apr;44(4):323-8
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Early duodenal adenocarcinoma arising in gastric metaplasia treated by endoscopic resection].
  • Most duodenal carcinomas are diagnosed at a more advanced stage.
  • This report describes the case of a 59-year-old lady with an early duodenal adenocarcinoma diagnosed at check-up gastroduodenoscopy in an outpatient clinic who was referred to us for further investigation and management.
  • Histopathological examination revealed the rare entity of an early duodenal carcinoma arising from incomplete-type gastric metaplasia in the duodenum.
  • In summary, the presented paper describes a case of successful endoscopic treatment of an early duodenal carcinoma arising from incomplete gastric metaplasia.
  • [MeSH-major] Adenocarcinoma / surgery. Duodenal Neoplasms / surgery. Endoscopy, Gastrointestinal. Stomach / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16625461.001).
  • [ISSN] 0044-2771
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


12. Paşalega M, Burdescu C, Meşină C, Mirea C, Tenea T, Vasile I: [Unusual late complication after esophagoplasty type Gavriliu II for esophageal stenosis from chemical burns--cancer of the esophagoplasty tube]. Chirurgia (Bucur); 2005 Mar-Apr;100(2):175-9
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Unusual late complication after esophagoplasty type Gavriliu II for esophageal stenosis from chemical burns--cancer of the esophagoplasty tube].
  • [Transliterated title] Complicaţie tardivă rară după esofagoplastie tip Gavriliu II pentru stenoză esofagiană postcaustică--cancerul tubului de esofagoplastie.
  • We present the case of a 56 year old female, who in 23 years after esophagoplasty type Gavriliu II, with pre-sternal tube for esophageal chemical burn stenosis, develops a cancer in the upper third of the gastric tube, with a fast evolution to malnutrition, through lumen obturation.
  • It is discussed the characteristic feature of the case: the difficulty of the stage-evolutive integration of this malignant disease location, the etiopathogenic factors that contributed to the malignant evolution of the antral portion of the gastro-esophagoplasty tube, the limits of the surgical treatment.
  • [MeSH-major] Adenocarcinoma / etiology. Burns, Chemical / complications. Esophageal Neoplasms / etiology. Esophageal Stenosis / surgery. Esophagogastric Junction. Esophagoplasty / adverse effects

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15957461.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


13. Fahlke J, Ridwelski K, Florschuetz A, Kettner E, Leithaeuser M, Kroehning H, Stuebs P, Zierau K, Lippert H: Cetuximab plus docetaxel-cisplatin (DC) as first-line treatment for locally advanced or metastatic gastric cancer: Preliminary results of a phase II study. J Clin Oncol; 2009 May 20;27(15_suppl):e15592

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cetuximab plus docetaxel-cisplatin (DC) as first-line treatment for locally advanced or metastatic gastric cancer: Preliminary results of a phase II study.
  • : e15592 Background: Based on promising published data, this multicenter, phase II study was initiated to investigate a combined treatment using DC and cetuximab in the first-line setting for patients with gastric cancer.
  • METHODS: Patients aged 18-75 years with stage III (T4, nonresectable) or stage IV gastric cancer, ECOG performance status (PS) ≤2, and life expectancy ≥3 months were recruited to receive cetuximab (400 mg/m<sup>2</sup> on day 1 then 250 mg/m<sup>2</sup> q1w) and DC (D 75 mg/m<sup>2</sup> and C 75 mg/m<sup>2</sup>; both as 1-h infusions on day 1 and then q3w).
  • RESULTS: Preliminary data are available for 30 patients; median age 64 [range: 40-73] years; median ECOG PS 1 [range: 0-2]; adenocarcinoma 87%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962888.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Leichman L, Goldman BH, Benedetti JK, Billingsley KG, Thomas CR, Iqbal S, Lenz H, Blanke C, Gold PJ, Corless CL: Oxaliplatin (OXP) plus protracted infusion 5-fluorouracil (PIFU) and external beam radiation (EBRT) prior to surgery (S) for potentially curable esophageal adenocarcinoma (EA): A Southwest Oncology Group (SWOG) phase II trial with molecular correlates (S0356). J Clin Oncol; 2009 May 20;27(15_suppl):4513

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxaliplatin (OXP) plus protracted infusion 5-fluorouracil (PIFU) and external beam radiation (EBRT) prior to surgery (S) for potentially curable esophageal adenocarcinoma (EA): A Southwest Oncology Group (SWOG) phase II trial with molecular correlates (S0356).
  • Based on phase I data, SWOG designed a phase II trial (S0356) to test OXP with PI5FU and EBRT for PTS with EA.
  • METHODS: Eligibility: clinical stage II/III EA, ≥ 18 years, Zubrod PS ≤ 2, standard hematologic/non-hematologic values, and tumor < 2 cm into the gastric cardia.
  • The trial used a 2-stage design; the trial was halted at 45 PTS to review pCR rate; it reopened to full accrual.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962704.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Shi H, Lu D, Shu Y, Shi W, Lu S, Wang K: Expression of multidrug resistance-related proteins p-glycoprotein, glutathione-s-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma. Hepatogastroenterology; 2008 Sep-Oct;55(86-87):1530-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of multidrug resistance-related proteins p-glycoprotein, glutathione-s-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
  • However, the clinical significance of the expression of MDR-related proteins p-glycoprotein (PGP), glutathione-s-transferases (GST-pi), topoisomerase-II (Topo-II) and lung resistance protein (LRP) in primary gastric cardiac adenocarcinoma (PGCA) remains unclear.
  • The expression of PGP, GST-pi, Topo-II and LRP in formalin-fixed paraffin-embedded tissue sections was determined by a labelled streptavidin-biotin immunohistochemical technique, and the results were analyzed in correlation with clinicopathological data.
  • RESULTS: The positive rates of expression of PGP, GST-pi, Topo-II and LRP in malignant tissues (49.2%, 75.4%, 68.1% and 58%, respectively) were all higher than that of the normal tissues (0, 30%, 20% and 0, respectively, P<0.01).
  • GST-pi expression status progressively increased with increasing differentiated degree (40%, 75.8% and 88.5%, P<0.05) and clinico pathologic stage (staging 1/2 vs. 3/4, 57.1% vs. 83.3%, P<0.05).
  • The expression of Topo-II was associated with increasing differentiated degree (33.3%, 69.7% and 80.7%, P<0.01).
  • No significant differences with Topo-II expression was found in relation to the clinicopathologic stage (staging 1/2 vs. 3/4, 57.1% vs. 72.9%, P>0.05) and lymphatic metastasis (with vs. without metastasis, 65.0% vs. 72.4%, P>0.05).
  • Moreover, a significant difference with the expression of LRP was found in relation to the clinicopathologic stage (staging 1/2 vs. 3/4, 38% vs. 66.6%, P<0.05), and lymphatic metastasis (with vs. without metastasis, 70.0% vs. 41.4%, P<0.05).
  • The positive rates of co-expression of PGP and GST-pi, PGP and Topo-II, PGP and LRP, GST-pi and Topo-II, LRP and GST-pi, LRP and Topo-II, PGP, GST-pi, Topo-II and LRP in malignant cells were 23.2%, 15.9%, 11.6%, 13.0%, 26.1%, 7.24%, 5.8%, respectively.
  • CONCLUSIONS: MDR-related proteins PGP, GST-pi, Topo-II and LRP are involved in multiple mechanisms of drug resistance in PGCA.
  • Combined determination of PGP, GST-pi, Topo-II and LRP may be prospectively valuable for optimizing the chemotherapy regimes, developing high quality anti-cancer drugs, and further predicting the outcomes of those patients with PGCA.
  • [MeSH-major] Adenocarcinoma / chemistry. Cardia / chemistry. DNA Topoisomerases, Type II / analysis. Glutathione S-Transferase pi / analysis. P-Glycoprotein / analysis. Stomach Neoplasms / chemistry. Vault Ribonucleoprotein Particles / analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19102336.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / P-Glycoprotein; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 5.99.1.3 / DNA Topoisomerases, Type II
  •  go-up   go-down


16. Ajani JA, Winter K, Okawara GS, Donohue JH, Pisters PW, Crane CH, Greskovich JF, Anne PR, Bradley JD, Willett C, Rich TA: Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol; 2006 Aug 20;24(24):3953-8
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response.
  • PURPOSE: Preoperative therapy for localized gastric cancer has considerable appeal.
  • PATIENTS AND METHODS: Patients with localized gastric adenocarcinoma were eligible.
  • Forty-nine patients were entered and 43 were assessable (12% stage IB; 37% stage II; and 52% stage III).
  • CONCLUSION: For localized gastric cancer, preoperative chemoradiotherapy strategy achieved a pathCR rate of more than 20% in a cooperative group setting.
  • With some refinements, this preoperative chemoradiotherapy strategy is poised for a randomized comparison with postoperative adjuvant chemoradiotherapy in patients with gastric cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gastrectomy. Neoadjuvant Therapy. Stomach Neoplasms / drug therapy. Stomach Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16921048.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA21661; United States / NCI NIH HHS / CA / U10 CA32115; United States / NCI NIH HHS / CA / U10 CA37422
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


17. Lai JF, Kim S, Li C, Oh SJ, Hyung WJ, Choi WH, Choi SH, Wang LB, Noh SH: Clinicopathologic characteristics and prognosis for young gastric adenocarcinoma patients after curative resection. Ann Surg Oncol; 2008 May;15(5):1464-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic characteristics and prognosis for young gastric adenocarcinoma patients after curative resection.
  • BACKGROUND: Conflicting results from previous studies on gastric adenocarcinoma (GC) in young patients have led to controversy surrounding the prognosis for young GC patients.
  • However, in regard to T4 invasion, N3 lymph node metastasis, and TNM stage IV, the characteristics of the tumors of young patients were similar to those of middle-aged and elderly patients.
  • Stratified by TNM stage, young patients showed better overall survival at stage I than middle-aged patients, and at stages I, II, and IIIa than elderly patients.
  • Young patients could gain a survival benefit after curative resection with stage I disease.
  • [MeSH-major] Adenocarcinoma / secondary. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18340495.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Guo W, Dong Z, Chen Z, Yang Z, Wen D, Kuang G, Guo Y, Shan B: Aberrant CpG island hypermethylation of RASSF1A in gastric cardia adenocarcinoma. Cancer Invest; 2009 May;27(4):459-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant CpG island hypermethylation of RASSF1A in gastric cardia adenocarcinoma.
  • In this work, the promoter methylation status of the RASSF1A in 92 gastric cardia adenocarcinoma (GCA) and corresponding normal tissues were investigated using Methylation-specific PCR (MSP) approach, immunohistochemistry method and RT-PCR were used respectively to examine the protein expression and mRNA expression of RASSF1A in tumors and corresponding normal tissues.
  • Methylation frequencies of stage III and IV tumor tissues were significantly higher than that in stage I and II tumor tissues (p <.05).
  • [MeSH-major] Adenocarcinoma / genetics. Cardia / chemistry. CpG Islands. DNA Methylation. Gene Expression Regulation, Neoplastic. Gene Silencing. Stomach Neoplasms / genetics. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19160099.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCND1 protein, human; 0 / RASSF1 protein, human; 0 / RNA, Messenger; 0 / Tumor Suppressor Proteins; 136601-57-5 / Cyclin D1
  •  go-up   go-down


19. Rivera F, Galán M, Tabernero J, Cervantes A, Vega-Villegas ME, Gallego J, Laquente B, Rodríguez E, Carrato A, Escudero P, Massutí B, Alonso-Orduña V, Cardenal A, Sáenz A, Giralt J, Yuste AL, Antón A, Aranda E, Spanish Cooperative Group for Digestive Tumor Therapy: Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma. Int J Radiat Oncol Biol Phys; 2009 Dec 1;75(5):1430-6
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma.
  • PURPOSE: To determine in a Phase II trial whether preoperative irinotecan-cisplatin (IC) followed by concurrent IC therapy and radiotherapy (IC/RT) improved outcome in patients with resectable, locally advanced gastric adenocarcinoma (GC) or esophagogastric junction cancer (EGJC).
  • PATIENTS AND METHODS: Patients with resectable Stage II-IV, M0 GC or EGJC made up the study population.
  • [MeSH-major] Adenocarcinoma. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophageal Neoplasms. Esophagogastric Junction. Stomach Neoplasms

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19540072.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


20. Shi H, Lu D, Shu Y, Shi W, Lu S, Wang K: Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma. Cancer Invest; 2008 May;26(4):344-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
  • However, the clinical significance of the expression of MDR-related proteins p-glycoprotein (PGP), glutathione-s-transferases (GST-pi), topoisomerase-II (Topo-II) and lung resistance protein (LRP) in primary gastric cardiac adenocarcinoma (PGCA) remains unclear.
  • The expression of PGP, GST-pi, Topo-II and LRP in formalin-fixed paraffin-embedded tissue sections was determined by a labelled streptavidin-biotin immunohistochemical technique, and the results were analyzed in correlation with clinicopathological data.
  • RESULTS: The positive rates of expression of PGP, GST-pi, Topo-II and LRP in malignant tissues (49.2%, 75.4%, 68.1% and 58%, respectively) were all higher than that of the normal tissues(0, 30%, 20% and 0, respectively, P < 0.01).
  • GST-pi expression status progressively increased with increasing differentiated degree (40%, 75.8% and 88.5%, P < 0.05) and clinicopathologic stage (staging 1/2 vs 3/4, 57.1% vs 83.3%, P < 0.05).
  • The expression of Topo-II was associated with increasing differentiated degree (33.3%, 69.7 and 80.7%, P < 0.01).
  • No significant differences with Topo-II expression were found in relation to the clinicopathologic stage (staging 1/2 vs 3/4, 57.1% vs 72.9%, P > 0.05) and lymphatic metastasis (with vs. without metastasis, 65.0% vs 72.4%, P > 0.05).
  • Moreover, a significant difference with the expression of LRP was found in relation to the clinicopathologic stage (staging 1/2 vs 3/4, 38% vs 66.6%, P < 0.05), and lymphatic metastasis (with vs without metastasis, 70.0% vs 41.4%, P < 0.05).
  • The positive rates of co-expression of PGP and GST-pi, PGP and Topo-II, PGP and LRP, GST-pi and Topo-II, LRP and GST-pi, LRP and Topo-II, PGP, GST-pi, Topo-II and LRP in malignant cells were 23.2%, 15.9%, 11.6%, 13.0, 26.1, 7.24, 5.8, respectively.
  • CONCLUSIONS: MDR-related proteins PGP, GST-pi, Topo-II alpha and LRP are involved in multiple mechanisms of drug resistance in PGCA.
  • Combined determination of PGP, GST-pi, Topo-II and LRP may be prospectively valuable for optimizing the chemotherapy regimes, developing high quality anti-cancer drugs, and further predicting the outcomes of those patients with PGCA.
  • [MeSH-major] Adenocarcinoma / chemistry. Cardia / chemistry. DNA Topoisomerases, Type II / analysis. Drug Resistance, Multiple / genetics. Drug Resistance, Neoplasm / genetics. Gene Expression Regulation, Neoplastic. Glutathione S-Transferase pi / analysis. Neoplasm Proteins / analysis. P-Glycoprotein / analysis. Stomach Neoplasms / chemistry. Vault Ribonucleoprotein Particles / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18443954.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / P-Glycoprotein; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; EC 2.5.1.18 / GSTP1 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 5.99.1.3 / DNA Topoisomerases, Type II
  •  go-up   go-down


21. Euanorasetr C, Lertsithichai P: Results of D2 gastrectomy for gastric adenocarcinoma: 10-year experience in Thai patients. J Med Assoc Thai; 2007 Feb;90(2):291-300
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of D2 gastrectomy for gastric adenocarcinoma: 10-year experience in Thai patients.
  • BACKGROUND: The therapeutic value of D2 gastrectomy in the curative treatment of gastric adenocarcinoma is controversial outside Japan.
  • MATERIAL AND METHOD: The authors retrospectively reviewed the medical records of 97 patients with gastric adenocarcinoma who underwent curative D2 gastrectomy between October 1995 and September 2005.
  • The 5-year disease-free survival rate for each TNM stage was 100% for stages IA and IB, 75% for stage II, 78% for stage IIIA, 28% for stage IIIB and 4% for stage IV.
  • CONCLUSION: The D2 gastrectomy can be performed with low morbidity and mortality, and may increase the cure rate and survival of Thai gastric adenocarcinoma patients, at least in experienced centers.
  • [MeSH-major] Adenocarcinoma / surgery. Gastrectomy / methods. Stomach Neoplasms / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17375634.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


22. Jeng YM, Wang TH, Lu SH, Yuan RH, Hsu HC: Prognostic significance of insulin-like growth factor II mRNA-binding protein 3 expression in gastric adenocarcinoma. Br J Surg; 2009 Jan;96(1):66-73
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of insulin-like growth factor II mRNA-binding protein 3 expression in gastric adenocarcinoma.
  • BACKGROUND: Insulin-like growth factor II mRNA-binding protein (IMP) 3 is expressed in embryonic tissues and multiple cancers.
  • The aim was to establish the prognostic value of IMP-3 expression in gastric adenocarcinoma.
  • METHODS: IMP-3 expression in resected gastric adenocarcinomas was analysed by immunohistochemistry.
  • IMP-3-positive tumours were associated with poorer 5-year survival than negative tumours at all stages (stage I, 82 versus 97 per cent; stage II, 55 versus 78 per cent; stage III and IV, 11 versus 25 per cent; P = 0.005, P = 0.033 and P = 0.036 respectively).
  • Multivariable analysis identified IMP-3 (hazard ratio (HR) 1.93), depth of tumour invasion (HR 3.69, 9.77 and 10.69 for pathological tumour stage (pT) 2, pT3 and pT4 respectively versus pT1), and lymph node metastasis (HR 1.57, 3.29 and 3.40 for pathological node stage (pN) 1, pN2 and pN3 respectively versus pN0) as independent prognostic factors.
  • CONCLUSION: IMP-3 expression correlates with the metastatic potential of gastric adenocarcinoma and is an independent prognostic factor.
  • [MeSH-major] Adenocarcinoma / metabolism. Insulin-Like Growth Factor Binding Protein 2 / metabolism. Insulin-Like Growth Factor Binding Protein 3 / metabolism. Stomach Neoplasms / metabolism

  • Genetic Alliance. consumer health - Factor II Deficiency.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
  • (PMID = 19109797.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Insulin-Like Growth Factor Binding Protein 2; 0 / Insulin-Like Growth Factor Binding Protein 3; 0 / RNA, Messenger
  •  go-up   go-down


23. Richards D, McCollum D, Wilfong L, Sborov M, Boehm KA, Zhan F, Asmar L: Phase II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer and/or adenocarcinoma of the gastroesophageal junction. Ann Oncol; 2008 Jan;19(1):104-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer and/or adenocarcinoma of the gastroesophageal junction.
  • BACKGROUND: Platinum-based chemotherapy is the standard treatment for advanced gastric cancer (GC).
  • PATIENTS AND METHODS: Patients with untreated stage IV GC or adenocarcinoma of the gastroesophageal junction (AGEJ) received docetaxel 60 mg/m(2) followed by oxaliplatin 130 mg/m(2) on day 1 of each 21-day cycle until progression or unacceptable toxicity.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CALCIUM GLUCONATE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. MAGNESIUM SULFATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17897959.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0 / Taxoids; 04ZR38536J / oxaliplatin; 15H5577CQD / docetaxel; 7487-88-9 / Magnesium Sulfate; 7S5I7G3JQL / Dexamethasone; SQE6VB453K / Calcium Gluconate
  •  go-up   go-down


24. Siewert JR, Feith M, Stein HJ: Biologic and clinical variations of adenocarcinoma at the esophago-gastric junction: relevance of a topographic-anatomic subclassification. J Surg Oncol; 2005 Jun 1;90(3):139-46; discussion 146
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biologic and clinical variations of adenocarcinoma at the esophago-gastric junction: relevance of a topographic-anatomic subclassification.
  • A topographic-anatomic subclassification of adenocarcinomas of the esophago-gastric junction (AEG) in distal esophageal adenocarcinoma (AEG Type I), true carcinoma of the cardia (AEG Type II), and subcardial gastric cancer (AEG Type III) was introduced in 1987 and is now increasingly accepted and used worldwide.
  • While underlying specialized intestinal metaplasia can be found in basically all patients with AEG Type I tumors, this is uncommon in Type II tumors and virtually absent in Type III tumors.
  • Stage distribution and overall long-term survival after surgical resection also shows marked differences between the AEG subtypes.
  • [MeSH-major] Adenocarcinoma / classification. Cardia. Esophageal Neoplasms / classification. Esophagogastric Junction. Stomach Neoplasms / classification

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc
  • (PMID = 15895452.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 35
  •  go-up   go-down


25. Nagahori Y, Nagahori K, Hamaguchi Y, Fukushima T, Masui H, Mogaki M, Abe T: [Efficacy of low-dose CDDP and CPT-11 for patients with intestinal type of gastric adenocarcinoma]. Gan To Kagaku Ryoho; 2008 Sep;35(9):1555-9
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of low-dose CDDP and CPT-11 for patients with intestinal type of gastric adenocarcinoma].
  • Several chemotherapy regimens combining CPT-11 and CDDP for advanced gastric cancer have been reported to demonstrate high response rates and high incidence of severe toxicity.
  • PATIENTS AND METHODS: Seven patients with histologically-confirmed intestinal type of gastric adenocarcinoma were enrolled in this study.
  • Six patients received combination chemotherapy with CPT-11 and CDDP after the gastrectomy (stage I b: 1, II : 3, III b: 1, IV: 1).
  • CONCLUSION: The combination of low-dose CDDP and CPT-11 has mild therapeutic toxicities and may achieve a prolonged median survival time in patients with intestinal- type gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Cisplatin / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18799911.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


26. Kostić Z, Cuk V, Bokun R, Ignjatović D, Usaj-Knezević S, Ignjatović M: [Detection of free cancer cells in peritoneal cavity in patients surgically treated for gastric adenocarcinoma]. Vojnosanit Pregl; 2006 Apr;63(4):349-56
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of free cancer cells in peritoneal cavity in patients surgically treated for gastric adenocarcinoma].
  • BACKGROUND/AIM: Peritoneal metastasis is a leading cause of therapeutic failure after an operative treatment of patients with gastric adenocarcinoma.
  • The aim of this study was to determine the frequency of the presence of free cancer cells in the peritoneal cavity in the patients surgically treated for gastric adenocarcinoma, and its relation to certain clinical, operative and pathohistological paramethers.
  • Immediately after the laparotomy, 200 ml physiologic saline, heated to 37 degrees C, was introduced into the abdominal cavity, mannualy dispersed and collected from the region around the gastric tumor and the pouch of Douglas.
  • The frequency of positive cytological findings was compared to the location and the diameter of the cancer, pathohistological type of carcinoma, pathohistological stage of the disease, lymph node and the liver and/or peritoneal metastases and the type of surgical procedure.
  • A statistically highly significant difference (p < or = 0.001) in the frequency of positive cytological finding was found between the groups of patients with and without cancer invasion of serosa, with cancer diameters > 5 cm and < or = 5 cm, in the stage of disease I, II and III, IV, with macroscopically present and without metastases, with re section and D2 lymphadenectomy and palliative procedure.
  • The results of the univariate analysis showed that the cancer diameter > 5 cm, tumor invasion of serosa, pathohistological stage of the disease III and IV and macroscopically visible metastases were the most important risk factors for the free cancer cells detection.
  • [MeSH-major] Adenocarcinoma / surgery. Neoplasm Seeding. Neoplastic Cells, Circulating. Peritoneal Cavity / cytology. Stomach Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Vojnosanit Pregl. 2006 Apr;63(4):347-8 [16683400.001]
  • (PMID = 16683401.001).
  • [ISSN] 0042-8450
  • [Journal-full-title] Vojnosanitetski pregled
  • [ISO-abbreviation] Vojnosanit Pregl
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


27. Patriti A, Ceccarelli G, Bellochi R, Bartoli A, Spaziani A, Di Zitti L, Casciola L: Robot-assisted laparoscopic total and partial gastric resection with D2 lymph node dissection for adenocarcinoma. Surg Endosc; 2008 Dec;22(12):2753-60
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Robot-assisted laparoscopic total and partial gastric resection with D2 lymph node dissection for adenocarcinoma.
  • BACKGROUND: Lymph node dissection and esophageal anastomosis, considered the more demanding steps of laparoscopic gastrectomy for gastric adenocarcinoma, can be performed with the use of a remote-controlled robot.
  • METHODS: Thirteen patients with a histologically proved gastric cancer (six stage I, six stage II, and one stage III) were enrolled in a prospective study to assess feasibility and safety of the Da Vinci surgical system in total and partial gastrectomy with extended lymph node dissection.
  • [MeSH-major] Adenocarcinoma / surgery. Gastrectomy / methods. Laparoscopy / methods. Lymph Node Excision / methods. Robotics / methods. Stomach Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Surg Endosc. 2009 Aug;23(8):1919-21; author reply 1922-3 [19444513.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):348-54 [17091331.001]
  • [Cites] N Engl J Med. 1999 Mar 25;340(12):908-14 [10089184.001]
  • [Cites] J Surg Oncol. 2008 Feb 1;97(2):169-72 [18095269.001]
  • [Cites] Am J Surg. 2007 Dec;194(6):839-44; discussion 844 [18005781.001]
  • [Cites] Br J Surg. 2004 Nov;91(11):1390-7 [15386325.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):645-50 [11395231.001]
  • [Cites] J Surg Oncol. 2005 Jun 1;90(3):139-46; discussion 146 [15895452.001]
  • [Cites] Arch Surg. 2003 Jul;138(7):777-84 [12860761.001]
  • [Cites] Br J Cancer. 1999 Mar;79(9-10):1522-30 [10188901.001]
  • [Cites] Int J Clin Pract. 2007 Feb;61(2):309-14 [17263718.001]
  • [Cites] Surg Endosc. 2008 Feb;22(2):436-42 [17593437.001]
  • [Cites] Surg Oncol. 1993;2 Suppl 1:13-8 [8252217.001]
  • [Cites] Surg Endosc. 2007 Sep;21(9):1662-6 [17345142.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2002 Feb;14(2):115-22 [11981334.001]
  • [Cites] J Thorac Cardiovasc Surg. 2004 Jun;127(6):1847-9 [15173760.001]
  • [Cites] Arch Surg. 2000 Jul;135(7):806-10 [10896374.001]
  • [Cites] Surg Endosc. 2007 Jul;21(7):1054-62 [17287918.001]
  • [Cites] Ann Surg Oncol. 2000 Apr;7(3):210-7 [10791852.001]
  • [Cites] Gastric Cancer. 2006;9(3):167-76 [16952034.001]
  • [Cites] Acta Biomed. 2004 Dec;75(3):188-91 [15796094.001]
  • [Cites] Surg Oncol. 2007 Aug;16(2):85-98 [17560103.001]
  • [Cites] Gastric Cancer. 2004;7(4):240-5 [15616772.001]
  • [Cites] Ann Surg. 2005 Feb;241(2):232-7 [15650632.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • [Cites] Surg Endosc. 2008 Mar;22(3):784-6 [17943373.001]
  • (PMID = 18813994.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


28. Wang Q, Gong L, Dong R, Qiao Q, He XL, Chu YK, Du XL, Yang Y, Zang L, Nan J, Lin C, Lu JG: Tissue microarray assessment of selenoprotein P expression in gastric adenocarcinoma. J Int Med Res; 2009 Jan-Feb;37(1):169-74
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue microarray assessment of selenoprotein P expression in gastric adenocarcinoma.
  • This study investigated selenoprotein P expression, using immunohistochemistry, in gastric adenocarcinoma tissue microarrays constructed from 30 gastric adenocarcinoma specimens and 30 normal gastric tissues (controls).
  • Selenoprotein P expression scores were significantly lower in gastric adenocarcinoma (17/30, 56.7%) than in control tissues (25/30, 83.3%).
  • Selenoprotein P was significantly more likely to be expressed in well-to-moderately differentiated cases (13/17, 76.5%) than in cases with low differentiation (4/13, 30.8%) and there was no significant difference in selenoprotein P expression between tumour node metastasis (TNM) stage I - II (11/19, 57.9%) and TNM stage III (6/11, 54.5%).
  • In conclusion, selenoprotein P expression was low in gastric adenocarcinoma tissues compared with control tissues and was related to the degree of gastric adenocarcinoma differentiation but not to TNM stage.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19215687.001).
  • [ISSN] 0300-0605
  • [Journal-full-title] The Journal of international medical research
  • [ISO-abbreviation] J. Int. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Selenoprotein P
  •  go-up   go-down


29. Huang CC, Lien HH, Wang PC, Yang JC, Cheng CY, Huang CS: Quality of life in disease-free gastric adenocarcinoma survivors: impacts of clinical stages and reconstructive surgical procedures. Dig Surg; 2007;24(1):59-65
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of life in disease-free gastric adenocarcinoma survivors: impacts of clinical stages and reconstructive surgical procedures.
  • AIM: To investigate health-related quality of life data of disease-free gastric adenocarcinoma survivors, with special emphasis on the roles of clinical stages and reconstructive surgical procedures.
  • METHODS: We performed a cross-sectional study in 51 disease-free gastric adenocarcinoma patients.
  • The Taiwan Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Cancer 30 (EORTC QLQ-C30) and the supplementary gastric cancer module QLQ-STO22 were used as outcome measures.
  • RESULTS: Patients with earlier-/advanced-stage diseases (American Joint Committee on Cancer stages I and II vs. III and IV) had a similar quality of life in terms of global health status and functional and symptomatic well-being.
  • Multivariate regression analyses also proved that proximal gastric preservation was predictive of better role function, less nausea/vomiting, and less appetite loss.
  • CONCLUSIONS: Gastric adenocarcinoma survivors may enjoy a similar life quality, regardless of their original disease stages.
  • [MeSH-major] Adenocarcinoma / surgery. Quality of Life. Reconstructive Surgical Procedures. Stomach Neoplasms / surgery. Survivors

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 S. Karger AG, Basel.
  • (PMID = 17369683.001).
  • [ISSN] 0253-4886
  • [Journal-full-title] Digestive surgery
  • [ISO-abbreviation] Dig Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


30. Al-Refaie WB, Tseng JF, Gay G, Patel-Parekh L, Mansfield PF, Pisters PW, Yao JC, Feig BW: The impact of ethnicity on the presentation and prognosis of patients with gastric adenocarcinoma. Results from the National Cancer Data Base. Cancer; 2008 Aug 1;113(3):461-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of ethnicity on the presentation and prognosis of patients with gastric adenocarcinoma. Results from the National Cancer Data Base.
  • BACKGROUND: Regional-based studies have indicated that ethnicity is associated with presentation and outcome in patients with gastric adenocarcinoma.
  • RESULTS: Between 1995 and 2002, 81,095 cases of gastric adenocarcinoma were entered into the NCDB.
  • In patients with stage I and II disease, the 5-year relative survival rates for APIs (stage I, 77.2%; stage II, 48%) were more favorable than for whites (stage I, 58.7%; stage II, 32.8%), African Americans (stage I, 55.9%; stage II, 37.9%), and Hispanics (stage I, 60.8%; stage II, 39.3%).
  • Predictors of a better outcome were Asian race, female sex, younger age, earlier stage, lower grade, distal tumors, multimodality treatment, and care at a teaching hospital.
  • CONCLUSIONS: Ethnicity was associated with differences in presentation and outcome of patients with gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / ethnology. Databases, Factual. Stomach Neoplasms / diagnosis. Stomach Neoplasms / ethnology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 American Cancer Society
  • (PMID = 18553367.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Büyükçelik A, Onur H, Akbulut H, Bülent Y, Ensari A, Utkan G, Onal BS, Içli F: Expression of p53 protein and DNA flow cytometry in gastric adenocarcinoma: implications in patients treated with adjuvant etoposide, adriamycin and cisplatin. Tumori; 2005 Jul-Aug;91(4):302-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of p53 protein and DNA flow cytometry in gastric adenocarcinoma: implications in patients treated with adjuvant etoposide, adriamycin and cisplatin.
  • AIMS AND BACKGROUND: We evaluated the prognostic value of p53 protein, DNA content and S-phase fraction in patients with adenocarcinoma of the stomach or the gastroesophageal junction treated with adjuvant etoposide, doxorubicin and cisplatin.
  • METHODS AND STUDY DESIGN: Thirty-five consecutive patients with stage II or III gastric or gastroesophageal junction adenocarcinoma treated with at least two cycles of adjuvant etoposide, doxorubicin and cisplatin after curative gastric resection were included.
  • P53 expression was detected in 42.9% (15 of 35) of gastric cancer tissues of the patients.
  • CONCLUSIONS: This trial supports the results of previous reports that p53 immunoreactivity is a prognostic factor for patients with adenocarcinoma of stomach or gastroesophageal junction treated with adjuvant chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. DNA, Neoplasm / analysis. Flow Cytometry. Stomach Neoplasms / drug therapy. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16277093.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Tumor Suppressor Protein p53; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


32. Lee J, Lee K, Kim W: Duodenal stump cancer after Billroth-II distal gastrectomy for gastric cancer. Gastric Cancer; 2009;12(2):118-22
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Duodenal stump cancer after Billroth-II distal gastrectomy for gastric cancer.
  • However, metachronous or even recurrent cancer at the duodenal stump following Billroth II type distal gastrec tomy for gastric cancer is extremely rare and, to our knowledge, has not yet been reported.
  • A 68-year-old man underwent Billroth II distal gastrectomy with D2 lymph node dissection for an advanced gastric cancer.
  • At that time the tumor stage was T2bN3M0, with 44 of 78 retrieved lymph nodes showing metastasis.
  • A polypoid tumor that bled easily when touched was found at the end of the afferent loop of the duodenal stump by gastrofiberscopic examination, and it was proven to be an adenocarcinoma by endoscopic biopsy.
  • [MeSH-major] Adenocarcinoma / pathology. Duodenal Neoplasms / pathology. Gastroenterostomy. Neoplasms, Second Primary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Gastroenterol. 2002 May-Jun;34(5):533-5 [11960064.001]
  • [Cites] J Surg Oncol. 2008 Aug 1;98(2):106-10 [18452218.001]
  • [Cites] Br J Surg. 1994 Oct;81(10):1472-4 [7820475.001]
  • [Cites] Radiographics. 2006 Jan-Feb;26(1):143-56 [16418249.001]
  • [Cites] Am J Surg. 2008 Jul;196(1):19-22 [18417082.001]
  • [Cites] Surgery. 1999 Feb;125(2):195-201 [10026754.001]
  • [Cites] Surg Today. 2000;30(8):735-8 [10955739.001]
  • [Cites] Am Surg. 1995 Apr;61(4):371-6 [7893109.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1427-34 [11745219.001]
  • [Cites] Br J Surg. 2000 Feb;87(2):236-42 [10671934.001]
  • [Cites] Oncology. 2003;65(2):113-7 [12931016.001]
  • [Cites] Arch Surg. 2000 Sep;135(9):1070-4; discussion 1074-5 [10982512.001]
  • [Cites] Clin Radiol. 2003 Mar;58(3):215-21 [12639527.001]
  • (PMID = 19562467.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


33. Yao JC, Tseng JF, Worah S, Hess KR, Mansfield PF, Crane CH, Schnirer II, Reddy S, Chiang SS, Najam A, Yu C, Giacco GG, Xie K, Wu TT, Feig BW, Pisters PW, Ajani JA: Clinicopathologic behavior of gastric adenocarcinoma in Hispanic patients: analysis of a single institution's experience over 15 years. J Clin Oncol; 2005 May 1;23(13):3094-103
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic behavior of gastric adenocarcinoma in Hispanic patients: analysis of a single institution's experience over 15 years.
  • PURPOSE: To determine the clinicopathologic behavior of gastric adenocarcinoma in Hispanics by comparing Hispanic and non-Hispanic patients treated at a single cancer center.
  • PATIENTS AND METHODS: Medical records of patients with invasive gastric cancer treated from 1985 to 1999 were reviewed.
  • Hispanics were less likely to have proximal gastric cancers compared with whites (38.9% v 59.5%, respectively; P < .005).
  • In Cox analyses, Asian race, earlier stage, papillary/tubular histology, distal location, and younger age were favorable predictors of survival.
  • CONCLUSION: Hispanic ethnicity does not impact survival in gastric adenocarcinoma.
  • However, histology, metastasis pattern, tumor localization, and other clinical parameters differ sufficiently to warrant further investigation into the epidemiology, pathogenesis, and molecular biology of gastric cancer in this population.
  • [MeSH-major] Adenocarcinoma / pathology. Hispanic Americans. Neoplasm Metastasis. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Hispanic American Health.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15860869.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


34. Lu HZ, Wu YP, Luo W, Han YL, Cai Y, Xu X, Liang J, Liu SM, Wang MR: [Correlation between aneuploidy of chromosome 17, over-expression of TP53 and TOPIIalpha, and the clinicopathological features and diagnosis of gastric adenocarcinoma]. Zhonghua Zhong Liu Za Zhi; 2009 Oct;31(10):754-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlation between aneuploidy of chromosome 17, over-expression of TP53 and TOPIIalpha, and the clinicopathological features and diagnosis of gastric adenocarcinoma].
  • OBJECTIVE: The purpose of this study was to investigate the markers which can be used in auxiliary diagnosis of gastric adenocarcinoma (GAC), and their correlation with their clinicopathological features.
  • METHODS: 122 surgical specimens including 99 gastric adenocarcinoma (GAC), 18 adjacent mucosa and 5 distal normal mucosa were collected, and analyzed by in situ hybridization (FISH).
  • RESULTS: The statistical results of FISH and TMA showed that 58.6% of cen17 in tumor tissues were aneuploid, and 45.5% of TP53 and 84.7% of TOPIIalpha were over-expressed in GAC samples, significantly higher than those in non-tumor gastric mucosa (0, 12.1% and 14.1%, respectively) (P = 0.000).
  • The expression of TP53 in non-tumor gastric mucosa with dysplasia was significantly higher than that in the mucosa without dysplasia (P = 0.009).
  • Higher frequency of aneuploidy of cen17 was also observed in the gastric cardia than in pylorus (P < 0.05), while no correlation was found between aneuploidy of cen17 and age, sex of patients, lymph node metastasis, and clinical stage of tumors.
  • CONCLUSION: Detection of aneuploidy of cen17 as well as over-expression of TP53 and TOPIIalpha may be helpful in the diagnosis and prognostic prediction of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma. Aneuploidy. Antigens, Neoplasm / metabolism. Chromosomes, Human, Pair 17 / genetics. DNA Topoisomerases, Type II / metabolism. DNA-Binding Proteins / metabolism. Stomach Neoplasms. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20021828.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; 0 / Tumor Suppressor Protein p53; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


35. Evtushenko VA, Vusik MV, Karakeshisheva MB, Pleshko RI, Ermolaeva LA: [Characteristic of inflammatory infiltrate of gastric mucosa in patients with grade II-III gastric dysplasia and of stomach cancer]. Klin Med (Mosk); 2008;86(11):48-53
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Characteristic of inflammatory infiltrate of gastric mucosa in patients with grade II-III gastric dysplasia and of stomach cancer].
  • The study included 85 inpatients and outpatients in whom composition of inflammatory infiltrate from gastric mucosa (GM) was determined at the Oncological Research Institute, Tomsk Research Centre of the Siberian Division, Russian Academy of Medical Sciences.
  • Group 1 comprised 21 patients with grade II-III GM epithelial dysplasia, group 2 - 24 patients having stomach cancer (histologically confirmed adenocarcinoma), group 3 - 19 patients with stage II-III mucinous gastric carcinoma, group 4 - 20 allegedly healthy subjects without signs of gastrointestinal pathology.
  • Mucinous gastric carcinoma was characterized by an increase of the number of neutrophils and macrophages.
  • Patients having adenocarcinoma of the stomach showed enhanced plasmocytic infiltration by plasmocytes with a low number of eosinophils and mast cells.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / pathology. Gastric Mucosa / pathology. Neoplasm Staging. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19177795.001).
  • [ISSN] 0023-2149
  • [Journal-full-title] Klinicheskaia meditsina
  • [ISO-abbreviation] Klin Med (Mosk)
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


36. Kunisaki C, Makino H, Kimura J, Takagawa R, Kosaka T, Ono HA, Akiyama H, Fukushima T, Nagahori Y, Takahashi M: Impact of lymphovascular invasion in patients with stage I gastric cancer. Surgery; 2010 Feb;147(2):204-11
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of lymphovascular invasion in patients with stage I gastric cancer.
  • BACKGROUND: Patients with stage I gastric cancer often suffer from tumor recurrence despite a generally favorable operative outcome.
  • METHODS: Between April 1985 and March 2000, a total of 1,880 patients with histologically proven stage I gastric cancer were included in this study.
  • RESULTS: Multivariate analysis in patients with all stage I gastric cancer revealed that depth of invasion, lymph node metastasis, and lymphovascular invasion independently influenced prognosis.
  • Moreover, advanced age was selected as an independent prognostic factor in patients with stage IA, and lymphovascular invasion in patients with stage IB gastric cancer by multivariate analyses.
  • The 5-year survival rates in stage T1N1 patients with moderate to severe lymphovascular invasion, T2N0 with moderate to severe lymphovascular invasion, and II were 95.1%, 83.5%, and 76.9%, respectively.
  • There was a significant difference in survival time between stage T1N1 and II (P = .0189) but not between stage T1N1 and T2N0 or stage T2N0 and II.
  • CONCLUSION: T2N0 gastric cancer patients with moderate to severe lymphovascular invasion may be suitable candidates for adjuvant chemotherapy.
  • [MeSH-major] Adenocarcinoma / pathology. Lymphatic Vessels / pathology. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Mosby, Inc. All rights reserved.
  • (PMID = 19878963.001).
  • [ISSN] 1532-7361
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Wang L, Li HG, Xia ZS, Lü J, Peng TS: IMP3 is a novel biomarker to predict metastasis and prognosis of gastric adenocarcinoma: a retrospective study. Chin Med J (Engl); 2010 Dec;123(24):3554-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IMP3 is a novel biomarker to predict metastasis and prognosis of gastric adenocarcinoma: a retrospective study.
  • BACKGROUND: Insulin-like growth factor-II mRNA-binding protein 3 (IMP3) is a newly identified mRNA-binding protein that is involved in embryogenesis and carcinogenesis of some malignant tumors.
  • The aim of this study was to detect the expression of IMP3 protein in gastric adenocarcinoma (GAC) and the correlation with clinicopathological features.
  • There was a significant TNM stage difference between GAC with and without IMP3 expression (P < 0.05).
  • Tumors with higher stage showed higher level of IMP3 expression.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / analysis. RNA-Binding Proteins / analysis. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22166630.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / IMP3 protein, human; 0 / Ki-67 Antigen; 0 / RNA-Binding Proteins
  •  go-up   go-down


38. Ueda Y, Fujimura T, Kinami S, Hirono Y, Yamaguchi A, Naitoh H, Tani T, Kaji M, Yamagishi H, Miwa K, Hokuriku-Kinki Immunochemo-Therapy Study Group-Gastric Cancer (HKIT-GC): A randomized phase III trial of postoperative adjuvant therapy with S-1 alone versus S-1 plus PSK for stage II/IIIA gastric cancer: Hokuriku-Kinki Immunochemo-Therapy Study Group-Gastric Cancer (HKIT-GC). Jpn J Clin Oncol; 2006 Aug;36(8):519-22
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized phase III trial of postoperative adjuvant therapy with S-1 alone versus S-1 plus PSK for stage II/IIIA gastric cancer: Hokuriku-Kinki Immunochemo-Therapy Study Group-Gastric Cancer (HKIT-GC).
  • In this randomized multicenter Phase III study, patients with curatively resected Stage II/IIIA gastric cancer were assigned to postoperative adjuvant therapy with an oral fluoropyrimidine S-1 alone (2 weeks of treatment and 1 week of rest for 6 months, followed by 2 weeks of treatment and 2 weeks of rest for 6 months) or S-1 combined with an oral biological response modifier PSK (the same regimen of S-1 plus daily PSK for 12 months).
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / administration & dosage. Immunologic Factors / administration & dosage. Immunotherapy. Oxonic Acid / administration & dosage. Proteoglycans / administration & dosage. Stomach Neoplasms / drug therapy. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16803844.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00216034
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Immunologic Factors; 0 / Proteoglycans; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 66455-27-4 / krestin
  •  go-up   go-down


39. Ohi S, Takahashi N, Ninomiya K, Nakajima M, Hashimoto H, Tachibana T, Yanaga K, Ishikawa H: Establishment and characterization of a cisplatin-resistant cell line (IGSK-1) from a poorly differentiated gastric adenocarcinoma. Hum Cell; 2007 Feb;20(1):15-22
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment and characterization of a cisplatin-resistant cell line (IGSK-1) from a poorly differentiated gastric adenocarcinoma.
  • We successfully established a spontaneously cisplatin-resistant tumor cell line (designated as IGSK-1) derived from original gastric carcinoma.
  • The histopathological diagnosis was gastric poorly differentiated adenocarcinoma accompanied with metastatic foci in lymph nodes, pT3, N2 M0, stage IIIB.
  • Spontaneously cisplatin-resistant gastric carcinoma cell line secreted gastrin and somatostatin is very important material for chemotherapy.
  • [MeSH-major] Adenocarcinoma / pathology. Antineoplastic Agents / pharmacology. Cell Line, Tumor. Cisplatin / pharmacology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1989 Dec 15;44(6):1100-3 [2606577.001]
  • [Cites] Cancer Res. 1975 Aug;35(8):2025-32 [1170940.001]
  • [Cites] Hum Cell. 1991 Mar;4(1):67-70 [1888706.001]
  • [Cites] Jpn J Exp Med. 1978 Feb;48(1):61-8 [209229.001]
  • [Cites] Cancer Res. 1990 May 1;50(9):2773-80 [2158397.001]
  • [Cites] Pathol Int. 2000 Oct;50(10):767-77 [11107048.001]
  • [Cites] Cancer Sci. 2004 Jul;95(7):575-82 [15245593.001]
  • [Cites] Hum Cell. 1989 Sep;2(3):307-9 [2562403.001]
  • [Cites] Int J Cell Cloning. 1987 Jul;5(4):322-34 [3497992.001]
  • [Cites] Hum Cell. 2005 Mar;18(1):35-44 [16130898.001]
  • [Cites] Acta Med Okayama. 1976 Jun;30(3):215-9 [136873.001]
  • [Cites] Jpn J Surg. 1988 Jul;18(4):438-46 [3172586.001]
  • [Cites] Gastroenterol Jpn. 1989 Apr;24(2):219 [2744340.001]
  • (PMID = 17506773.001).
  • [ISSN] 0914-7470
  • [Journal-full-title] Human cell
  • [ISO-abbreviation] Hum. Cell
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Gastrins; 51110-01-1 / Somatostatin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


40. Solerio D, Camandona M, Gasparri G, Casalegno PA, Raggio E, Dei Poli M: [The choice of surgical therapy in adenocarcinoma of the cardia]. Minerva Chir; 2005 Feb;60(1):17-22
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The choice of surgical therapy in adenocarcinoma of the cardia].
  • [Transliterated title] La scelta della terapia chirurgica nell'adenocarcinoma del cardias.
  • AIM: From 1996 the adenocarcinoma of the esophago-gastric junction (AEG) is divided into 3 types according to Siewert's classification.
  • For AEG type I and III the surgical treatment is codified, while for type II is still controversial.
  • The aim of our study is to understand what is the better surgical treatment for AEG type II.
  • METHODS: From 1990 to 2002 we have performed 111 resections for adenocarcinoma of the cardia: 25 for AEG type I (all esophago-gastric resection), 39 for type II (22 esophago-gastric resection, 17 extended total gastrectomy with esophageal resection) and 47 for type III (8 esophago-gastric resection, 39 extended total gastrectomy with esophageal resection).
  • For AEG type II any significant difference in survival is associated with surgical strategy, also in early stage (p>0.01).
  • CONCLUSIONS: According to the results of our study and those of the other authors, who have showed that a 10 cm distance of the neoplasm by the gastric side and the esophageal one could assure oncologic radicality and also that metastatic lymph nodes below pylorus and near greater curvature are uncommon, we can consider esophago-gastric resection for AEG II a speedy, safe and oncologically correct surgical treatment.
  • [MeSH-major] Adenocarcinoma / surgery. Cardia. Esophageal Neoplasms / surgery. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15902049.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


41. Dassen AE, Lemmens VE, van de Poll-Franse LV, Creemers GJ, Brenninkmeijer SJ, Lips DJ, Vd Wurff AA, Bosscha K, Coebergh JW: Trends in incidence, treatment and survival of gastric adenocarcinoma between 1990 and 2007: a population-based study in the Netherlands. Eur J Cancer; 2010 Apr;46(6):1101-10
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in incidence, treatment and survival of gastric adenocarcinoma between 1990 and 2007: a population-based study in the Netherlands.
  • BACKGROUND: Survival of gastric cancer in the Western world remains poor.
  • We conducted a retrospective population-based study to evaluate trends in incidence, treatment and outcome of gastric adenocarcinoma.
  • METHODS: All patients diagnosed with gastric adenocarcinoma during 1990-2007 in the Dutch Eindhoven Cancer Registry area were included (n=4,797).
  • Stage distribution worsened over time among patients with cardia (stages I and II: 32% in 1990-1993 and 22% in 2006-2007, p=0.005) and non-cardia (stage IV: 33% in 1990-1993 and 40% in 2006-2007, p=0.0003) cancer.
  • Age and stage had significant influence on survival after stratification for tumour localisation.
  • After adjustments for relevant factors (i.e. stage), the risk of death decreased since the late 90s for patients with a cardia tumour (hazard ratio 0.8, p=0.01).
  • [MeSH-major] Adenocarcinoma. Stomach Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20219351.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


42. Linder N, Haglund C, Lundin M, Nordling S, Ristimäki A, Kokkola A, Mrena J, Wiksten JP, Lundin J: Decreased xanthine oxidoreductase is a predictor of poor prognosis in early-stage gastric cancer. J Clin Pathol; 2006 Sep;59(9):965-71
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased xanthine oxidoreductase is a predictor of poor prognosis in early-stage gastric cancer.
  • AIM: To assess the clinical relevance of XOR expression in gastric cancer.
  • METHODS: XOR levels were studied by immunohistochemistry in tissue microarray specimens of 337 patients with gastric cancer and the relation between XOR expression and a series of clinicopathological variables, as well as disease-specific survival, was assessed.
  • Decreased XOR was associated with advanced stage, deep tumour penetration, diffusely spread tumour location, positive lymph node status, large tumour size, non-curative disease, cellular aneuploidy, high S-phase fraction and high cyclooxygenase-2 expression, but not with p53 expression or Borrmann classification.
  • Down regulation of XOR was associated with unfavourable outcome, and the cumulative 5-year gastric cancer-specific survival in patients with strong XOR expression was 47%, compared with 22% in those with moderate to negative expression (p<0.001).
  • This was also true in patients with stage I-II (p = 0.01) and lymph node-negative (p = 0.02) disease, as well as in patients with smaller (< or =5 cm) tumours (p = 0.02).
  • CONCLUSION: XOR expression in gastric cancer may be a new marker for a more aggressive gastric cancer biology, similar to that previously reported for breast cancer.
  • [MeSH-major] Adenocarcinoma / enzymology. Biomarkers, Tumor / metabolism. Stomach Neoplasms / enzymology. Xanthine Oxidase / metabolism
  • [MeSH-minor] Aged. Cytoplasm / enzymology. Female. Follow-Up Studies. Gastric Mucosa / enzymology. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Protein Array Analysis / methods. Survival Analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2001 Mar;158(3):849-53 [11238034.001]
  • [Cites] Clin Cancer Res. 2005 Jun 15;11(12):4372-81 [15958620.001]
  • [Cites] Genes Dev. 2002 Dec 15;16(24):3223-35 [12502743.001]
  • [Cites] Oncology. 2003;64(3):245-50 [12697965.001]
  • [Cites] Am J Physiol Cell Physiol. 2003 Jul;285(1):C48-55 [12637268.001]
  • [Cites] FEBS Lett. 1975 Nov 15;59(2):245-9 [179860.001]
  • [Cites] Cancer Res. 1976 Dec;36(12):4639-46 [187329.001]
  • [Cites] Life Sci. 1978 Aug 21;23(7):729-36 [692291.001]
  • [Cites] Cancer Res. 1981 Mar;41(3):854-9 [7459871.001]
  • [Cites] Cancer Res. 1986 Aug;46(8):3838-41 [3460692.001]
  • [Cites] J Clin Invest. 1992 Jan;89(1):197-202 [1370294.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3362-6 [1314387.001]
  • [Cites] J Immunol. 1994 Aug 15;153(4):1789-97 [8046245.001]
  • [Cites] Cytogenet Cell Genet. 1995;68(1-2):61-3 [7956361.001]
  • [Cites] Lab Invest. 1996 Jan;74(1):48-56 [8569197.001]
  • [Cites] Eur J Cancer. 1996 Feb;32A(2):215-20 [8664030.001]
  • [Cites] Anticancer Res. 1997 Jul-Aug;17(4B):2923-6 [9329565.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Lab Invest. 1999 Aug;79(8):967-74 [10462034.001]
  • [Cites] Nature. 1957 Oct 12;180(4589):763-4 [13477276.001]
  • [Cites] Am J Gastroenterol. 2002 Aug;97(8):2079-85 [12190180.001]
  • (PMID = 16935971.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.17.3.2 / Xanthine Oxidase
  • [Other-IDs] NLM/ PMC1860491
  •  go-up   go-down


43. Coburn NG, Govindarajan A, Law CH, Guller U, Kiss A, Ringash J, Swallow CJ, Baxter NN: Stage-specific effect of adjuvant therapy following gastric cancer resection: a population-based analysis of 4,041 patients. Ann Surg Oncol; 2008 Feb;15(2):500-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage-specific effect of adjuvant therapy following gastric cancer resection: a population-based analysis of 4,041 patients.
  • BACKGROUND: Adjuvant chemoradiotherapy improved survival in patients with resected gastric adenocarcinoma in the Southwest Oncology Group/Intergroup 0116 trial.
  • METHODS: Patients 18-85 years old who had undergone resection of non-metastatic gastric adenocarcinoma between May 2000 and December 2003, were identified from the Surveillance Epidemiology and End Results (SEER) database.
  • Patients who had received pre-operative irradiation, had unknown stage or radiation status, or had a survival of 3 months or less from the date of diagnosis were excluded.
  • RESULTS: Of 4,041 patients, there was improved survival for those receiving adjuvant irradiation for stages III and IVM0, with a median OS of 31 versus 24 months (P = 0.005) and 20 versus 15 months (P < 0.001), respectively, and a trend for improved survival in univariate analysis of stage II (P = 0.0535).
  • Adjusted analysis using a propensity score suggested that the benefit of adjuvant irradiation was similar in stage-II and -III patients.
  • However, there was no statistical improvement in survival for stage-Ib and -II patients who had received adjuvant irradiation.
  • CONCLUSIONS: In this population-based analysis, adjuvant radiotherapy for stage-III and IVM0 gastric cancer significantly improved OS.
  • Analysis of stage-Ib and -II patients is limited by small numbers, but there may not be the same benefit.
  • [MeSH-major] Adenocarcinoma / surgery. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2008 Sep;15(9):2622-3 [18431608.001]
  • (PMID = 18026800.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Röcken C, Röhl FW, Diebler E, Lendeckel U, Pross M, Carl-McGrath S, Ebert MP: The angiotensin II/angiotensin II receptor system correlates with nodal spread in intestinal type gastric cancer. Cancer Epidemiol Biomarkers Prev; 2007 Jun;16(6):1206-12
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The angiotensin II/angiotensin II receptor system correlates with nodal spread in intestinal type gastric cancer.
  • We aimed to substantiate the putative significance of angiotensin II receptor type 1 (AT1R) and type 2 (AT2R) for gastric cancer biology by investigating the correlation of their expression with various clinicopathologic variables and patient survival.
  • Local expression of AT1R, AT2R, and angiotensin-converting enzyme (ACE) was investigated by immunohistochemistry in tumor and corresponding nontumor specimens obtained from 100 patients with gastric cancer, and compared with the ACE insertion/deletion gene polymorphism.
  • AT1R was significantly more prevalent (P < 0.001) in intestinal type gastric cancer than in diffuse type gastric cancer.
  • In intestinal type gastric cancer, its expression correlated with the N category (P = 0.009) and the International Union Against Cancer tumor stage (P = 0.024).
  • AT1R+ intestinal type gastric cancers had a larger number of lymph node metastases (P = 0.026), a higher International Union Against Cancer tumor stage (P = 0.032), and a shorter survival time (P = 0.009) than AT1R- tumors.
  • Irrespective of the genotype, AT1R+ gastric cancers had a relative risk of lymph node metastases of 4.40 (95% confidence interval, 1.30-14.86).
  • Our study shows that AT1R and AT2R are expressed locally in gastric cancer and that the combination of AT1R expression and ACE I/D gene polymorphism correlates with nodal spread in intestinal type gastric cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Angiotensin II / metabolism. Genetic Predisposition to Disease. Peptidyl-Dipeptidase A / genetics. Receptors, Angiotensin / metabolism. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17548686.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Angiotensin; 11128-99-7 / Angiotensin II; EC 3.4.15.1 / Peptidyl-Dipeptidase A
  •  go-up   go-down


45. Park DJ, Kong SH, Lee HJ, Kim WH, Yang HK, Lee KU, Choe KJ: Subclassification of pT2 gastric adenocarcinoma according to depth of invasion (pT2a vs pT2b) and lymph node status (pN). Surgery; 2007 Jun;141(6):757-63
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subclassification of pT2 gastric adenocarcinoma according to depth of invasion (pT2a vs pT2b) and lymph node status (pN).
  • BACKGROUND: We investigated prognostic differences according to nodal status in patients with pT2a and pT2b stage gastric cancers.
  • METHODS: The clinicopathologic outcomes of 1118 patients who underwent curative resection and had 15 or more lymph nodes evaluated for pT2 stage gastric cancers between 1986 and 1996 were reviewed retrospectively.
  • Of the study group, 442 (39.5%) patients had pT2a stage gastric cancers and 676 (60.5%) had pT2b stage gastric cancers.
  • The prognosis of patients with pT2a gastric cancers was significantly better than that of patients with pT2b cancers on any pN stage (P < .001).
  • Multivariate analysis identified age, pT, and pN stages as independent prognostic factors for patients with pT2 gastric cancers.
  • Patients with pT2aN0 (stage IB) cancers showed the best survival.
  • Patents with pT2aN1 (stage II) and pT2bN0 (stage IB) cancers had similar survival rates, as did patients with pT2aN2 (stage IIIA) and pT2bN1 (stage II) cancers.
  • CONCLUSIONS: The subclassification of pT2 gastric cancers into pT2a or pT2b is necessary to demonstrate their different prognoses.
  • We propose that the current stage grouping should be modified to better represent the prognosis for patients with stage pT2 gastric cancers.
  • [MeSH-major] Adenocarcinoma / classification. Adenocarcinoma / pathology. Lymph Nodes / pathology. Stomach Neoplasms / classification. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17560252.001).
  • [ISSN] 0039-6060
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


46. Rohatgi PR, Mansfield PF, Crane CH, Wu TT, Sunder PK, Ross WA, Morris JS, Pisters PW, Feig BW, Gunderson LL, Ajani JA: Surgical pathology stage by American Joint Commission on Cancer criteria predicts patient survival after preoperative chemoradiation for localized gastric carcinoma. Cancer; 2006 Oct 1;107(7):1475-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical pathology stage by American Joint Commission on Cancer criteria predicts patient survival after preoperative chemoradiation for localized gastric carcinoma.
  • BACKGROUND: Preoperative chemoradiation for localized gastric cancer can modify baseline stage, as determined by surgical pathology stage.
  • Therefore, the authors hypothesized that surgical pathology stage would be a better prognosticator of overall survival (OS) than baseline stage.
  • Patients must have had localized gastric adenocarcinoma and were staged extensively, including endoscopic ultrasonography and laparoscopy.
  • OS was correlated with pretreatment and posttreatment parameters, including surgical pathology stage according to American Joint Commission on Cancer criteria.
  • None of the pretreatment parameters correlated with OS; however, longer OS correlated with lower pathologic stage (P < .0001), R0 resection (P < .001), clinical response noted prior to surgery (P = .002), pathCR (P = .004), lower pathologic lymph node classification (P = .006), and lower pathologic tumor classification (P = .03).
  • Pathologic stage and R0 resection were independent prognostic factors for OS (multivariate Cox model; both P = .05).
  • CONCLUSIONS: When preoperative chemoradiation strategy was employed for gastric cancer, the surgical pathology stage, a reflection of cancer's biologic heterogeneity, was a better prognosticator of OS than the baseline clinical stage.
  • Surgical pathology stage, in this setting, may serve as an intermediate endpoint for Phase II/III trials.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 16944539.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


47. Orditura M, De Vita F, Muto P, Vitiello F, Murino P, Lieto E, Vecchione L, Romano A, Martinelli E, Renda A, Ferraraccio F, Del Genio A, Ciardiello F, Galizia G: Adjuvant chemoradiotherapy in patients with stage III or IV radically resected gastric cancer: a pilot study. Arch Surg; 2010 Mar;145(3):233-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemoradiotherapy in patients with stage III or IV radically resected gastric cancer: a pilot study.
  • BACKGROUND: Adjuvant chemoradiotherapy does not represent the standard of care in patients with resected high-risk gastric cancer; however, results from phase 2 and randomized trials suggest improvement in overall survival.
  • We assessed the feasibility and toxic effects of chemoradiotherapy as adjuvant treatment in locally advanced gastric cancer.
  • PATIENTS: Twenty-nine patients with T4N+ or any TN23 gastric cancer previously treated with potentially curative surgery were enrolled.
  • Long-term outcome was related to TNM stage, basal serum tumor marker level, and, particularly, lymph node ratio.
  • CONCLUSION: A multimodal approach with FOLFOX-4 and radiotherapy is feasible and effective for the treatment of patients with resected high-risk gastric cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Stomach Neoplasms / drug therapy. Stomach Neoplasms / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Surg. 2010 Mar;145(3):239 [20329345.001]
  • (PMID = 20231623.001).
  • [ISSN] 1538-3644
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Zheng B, Chen YB, Hu Y, Wang JY, Zhou ZW, Fu JH: [Trend analysis for clinical characteristics and prognosis of adenocarcinoma of cardia]. Chin J Cancer; 2010 Jan;29(1):94-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Trend analysis for clinical characteristics and prognosis of adenocarcinoma of cardia].
  • BACKGROUND AND OBJECTIVE: The incidence of adenocarcinoma of the cardia has recently increased.
  • This study compared the clinicopathology and prognosis of patients with gastric cardia adenocarcinoma in different periods between 1984 and 2003.
  • METHODS: A total of 589 patients with pathologically confirmed gastric cardia adenocarcinoma hospitalized in Sun Yat-sen University Cancer Center between 1984 and 2003 were divided into 5-year groups.
  • The rates of patients with the stage-I and -II disease changed insignificantly, while patients with stage-III disease increased, and patients with stage-I disease decreased.
  • CONCLUSIONS: During the past 20 years, associated with the upward-trending incidence of gastric cardia adenocarcinoma, the admission rate at our hospital of patients with the tumor increased.
  • The proportion of patients with late-stage disease decreased and prognosis has improved.
  • [MeSH-major] Adenocarcinoma. Cardia / pathology. Stomach Neoplasms

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20038318.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


49. Butte JM, Becker F, Visscher A, Waugh E, Meneses M, Court I, Parada H, DE LA Fuente H: [Adenocarcinoma of the esophagogastric junction: retrospective analysis of 39 patients]. Rev Med Chil; 2010 Jan;138(1):53-60
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenocarcinoma of the esophagogastric junction: retrospective analysis of 39 patients].
  • BACKGROUND: The long-term survival of adenocarcinoma of the esophago-gastric junction is poor and depends on the possibility of performing a complete surgical excision and the absence of lymph node involvement.
  • AIM: To report surgical results and survival of patients with adenocarcinoma of the esophago-gastric junction.
  • MATERIAL AND METHODS: Retrospective review of medical records of patients with adenocarcinoma of the esophago-gastric junction, subjected to a curative surgical procedure between 2000 and 2008.
  • Tumor stage was determined using TNM and Siewert pathological classifications.
  • According to Siewert classification, seven patients had type I, six type II and 26 type III tumors.
  • According to postoperative staging, five patients were in stage I, 12 in stage II, nine in stage III and 13 in stage IV.
  • Well differentiated and stage I tumors had a better survival.
  • CONCLUSIONS: Among patients with adenocarcinoma of the esophago-gastric junction, type III tumors, lymph node involvement and vascular permeations are associated with a lower survival.
  • [MeSH-major] Adenocarcinoma / surgery. Esophageal Neoplasms / surgery. Esophagectomy / mortality. Esophagogastric Junction / surgery. Gastrectomy / mortality. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20361151.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Chile
  •  go-up   go-down


50. Johansson J, Djerf P, Oberg S, Zilling T, von Holstein CS, Johnsson F, Walther B: Two different surgical approaches in the treatment of adenocarcinoma at the gastroesophageal junction. World J Surg; 2008 Jun;32(6):1013-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two different surgical approaches in the treatment of adenocarcinoma at the gastroesophageal junction.
  • BACKGROUND: Adenocarcinoma at the gastroesophageal junction may be regarded as of esophageal or of gastric origin, and tumor removal may follow the principles of esophagectomy or extended gastrectomy.
  • METHODS: Baseline patient and tumor characteristics were collected, and tumors were categorized according to Siewert's classification (I, II, or III) of gastroesophageal junction tumors.
  • Ninety-six patients with type I (n = 67), II (n = 26), and III (n = 3) tumors underwent esophagectomy and gastric tube reconstruction, and 37 patients with type I (n = 5), II (n = 26), and III (n = 6) tumors underwent extended gastrectomy and long Roux-en-Y reconstructions.
  • RESULTS: After adjusting for the independently significant impact factors-tumor stage, tumor dissection (R0-R2), and length of tumor free resection margins-we did not find any specific survival benefit associated with either of the two evaluated surgical approaches for tumor resection and reconstruction.
  • CONCLUSIONS: Provided that adequate tumor dissection is performed, patients with adenocarcinoma at the gastroesophageal junction can be resected and reconstructed using the principles for esophagectomy or extended gastrectomy.
  • [MeSH-major] Adenocarcinoma / surgery. Esophageal Neoplasms / surgery. Esophagogastric Junction / surgery. Stomach Neoplasms / surgery


51. Carboni F, Lorusso R, Santoro R, Lepiane P, Mancini P, Sperduti I, Santoro E: Adenocarcinoma of the esophagogastric junction: the role of abdominal-transhiatal resection. Ann Surg Oncol; 2009 Feb;16(2):304-10
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the esophagogastric junction: the role of abdominal-transhiatal resection.
  • The surgical strategy for adenocarcinoma of the esophagogastric junction is still controversial.
  • The aim of this study was to evaluate surgical results of the abdominal-transhiatal approach for 100 consecutively operated type II and III cardia adenocarcinoma, to clarify clinicopathological differences between these tumors, and to define prognostic factors.
  • A prospectively maintained database identified 100 consecutively operated patients with Siewert type II and III cardia adenocarcinoma.
  • Concerning clinicopathological characteristics, only the incidence of T1-2 stage was significantly higher in Siewert II type (P = .006).
  • Overall actuarial 5-year survival rate in resected patients was 27.4% (median 27 months), with 20.6% for type II and 34 for type III cancers (P = .07).
  • Considering R0 resections, overall actuarial 5-year survival rate was 33.9% (median 33 months), with 26.7% for type II and 40.5 for type III cancer (P = .06).
  • Pathologic T and N stage and R status were independent prognostic factors by multivariate analysis, and Siewert type showed a trend toward significance.
  • True carcinoma of the cardia may be a distinct clinical entity with a more aggressive natural history than subcardial gastric carcinoma.
  • [MeSH-major] Adenocarcinoma / surgery. Digestive System Surgical Procedures. Esophagogastric Junction / surgery. Stomach Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2009 Jul;16(7):2074-5; author reply 2076 [19365623.001]
  • (PMID = 19050964.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Isgüder AS, Nazli O, Tansug T, Bozdag AD, Onal MA: Total gastrectomy for gastric carcinoma. Hepatogastroenterology; 2005 Jan-Feb;52(61):302-4
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Total gastrectomy for gastric carcinoma.
  • BACKGROUND/AIMS: Gastric cancer is one of the most common organ cancers all around the world and surgical resection is essential for treatment.
  • Total gastrectomy is the procedure of choice for treatment of proximal gastric cancer.
  • METHODOLOGY: Thirty-eight gastric cancer patients underwent total gastrectomy in the Third Surgical Clinic of Izmir Ataturk Training and Research Hospital between 1996 and 2001.
  • Age, gender, location of the tumor, histopathological findings, TNM stage, type of anastomosis, operation time, blood transfusions, oral food intake, postoperative hospital stay, morbidity, mortality both early and late, and survival rate were evaluated.
  • Histological types were adenocarcinoma (97.4%), and squamous cell carcinoma (2.6%).
  • TNM stages were: stage la 2.6%, stage II 7.9%, stage IIIa 39.5%, stage IIIb 42.1%, and stage IV 7.9%.
  • Gastric tubes were removed on the fourth postoperative day.
  • 89.5% of our cases were stage III or IV resulting in a low survival rate.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Gastrectomy. Stomach Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15783055.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


53. Konings IR, van der Gaast A, van der Wijk LJ, de Jongh FE, Eskens FA, Sleijfer S: The addition of pravastatin to chemotherapy in advanced gastric carcinoma: a randomised phase II trial. Eur J Cancer; 2010 Dec;46(18):3200-4
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The addition of pravastatin to chemotherapy in advanced gastric carcinoma: a randomised phase II trial.
  • This randomised phase II trial compared the efficacy and safety of pravastatin added to epirubicin, cisplatin and capecitabine (ECC versus ECC+P) in patients with advanced gastric carcinoma.
  • For early termination in case of futility, a two-stage design was applied (P(0) = 50%; P(1) = 70%; α = 0.05; β = 0.10).
  • PFR(6 months) was 6/14 patients (42.8%) in the ECC+P arm, and 7/15 patients (46.7%) in the control arm, and therefore the study was terminated after the first stage.
  • CONCLUSION: In this randomised phase II trial the addition of pravastatin to ECC did not improve outcome in patients with advanced gastric cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20727735.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 3Z8479ZZ5X / Epirubicin; 6804DJ8Z9U / Capecitabine; KXO2KT9N0G / Pravastatin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


54. Reynolds JV, Ravi N, Muldoon C, Larkin JO, Rowley S, O'Byrne K, Hollywood D, O'Toole D: Differential pathologic variables and outcomes across the spectrum of adenocarcinoma of the esophagogastric junction. World J Surg; 2010 Dec;34(12):2821-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential pathologic variables and outcomes across the spectrum of adenocarcinoma of the esophagogastric junction.
  • BACKGROUND: Adenocarcinoma of the esophagogastric junction (AEG) as described by Siewert et al. is classified as one entity in the latest (7th Edition) American Joint Cancer Committee/International Union Against Cancer (AJCC/UICC) manual, compared with the previous mix of esophageal and gastric staging systems.
  • The origin of AEG tumors, esophageal or gastric, and their biology remain controversial, particularly for AEG type II (cardia) tumors.
  • METHODS: We adapted a large prospective database (n = 520: 180 type I, 182 type II, 158 type III) to compare AEG tumors under the new TNM system Pathological variables associated with prognosis were compared (pT, pN, stage, differentiation, R status, lymphovascular invasion, perineural involvement, number of positive nodes, percent of positive nodes, and tumor length), as well as overall survival.
  • RESULTS: Compared with AEG type I tumors, type II and type III tumors had significantly (p < 0.05) more advanced pN stages, greater number and percentage of positive nodes, poorer differentiation, more radial margin involvement, and more perineural invasion.
  • In AEG type I, 14/180 patients (8%) had >6 involved nodes (pN3), compared with 16 and 30% of patients classified type II and III, respectively.
  • Median survival was significantly (p = 0.03) improved for type I patients (38 months) compared with those with tumors classified as type II (28 months) and type III (24 months).
  • CONCLUSIONS: In this series AEG type I is associated with more favorable pathologic features and improved outcomes compared with AEG type II and III.
  • [MeSH-major] Adenocarcinoma / pathology. Esophageal Neoplasms / pathology. Esophagogastric Junction / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] World J Surg. 2011 Jun;35(6):1409-10; author reply 1411 [21301836.001]
  • [Cites] Ann Surg. 2009 Nov;250(5):729-37 [19801928.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Oct;20 Suppl 5:55-60; discussion 61-2 [15456465.001]
  • [Cites] Am J Surg Pathol. 2007 Apr;31(4):569-75 [17414104.001]
  • [Cites] J Thorac Cardiovasc Surg. 2009 Sep;138(3):594-602; discussion 601-2 [19698841.001]
  • [Cites] Ann Surg. 2007 Jul;246(1):1-8 [17592282.001]
  • [Cites] World J Surg Oncol. 2006 Nov 21;4:82 [17118194.001]
  • [Cites] Ann Surg. 2007 May;245(5):707-16 [17457163.001]
  • [Cites] Oncology. 2010;78(1):26-33 [20185938.001]
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Cancer. 1994 Jun 1;73(11):2680-6 [8194005.001]
  • [Cites] Ann Oncol. 2009 May;20(5):885-91 [19164454.001]
  • [Cites] Ann Thorac Surg. 2007 May;83(5):1814-9 [17462405.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] J Am Coll Surg. 2007 Oct;205(4 Suppl):S49-53 [17916519.001]
  • [Cites] Ann Surg. 2008 Feb;247(2):365-71 [18216546.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • [Cites] Br J Surg. 2005 Jan;92(1):60-7 [15584066.001]
  • [Cites] Ann Surg. 2008 Oct;248(4):549-56 [18936567.001]
  • [Cites] Hum Pathol. 2006 Jan;37(1):40-7 [16360414.001]
  • [Cites] Ann Surg. 2000 Sep;232(3):353-61 [10973385.001]
  • (PMID = 20827475.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Barbour AP, Rizk NP, Gonen M, Tang L, Bains MS, Rusch VW, Coit DG, Brennan MF: Lymphadenectomy for adenocarcinoma of the gastroesophageal junction (GEJ): impact of adequate staging on outcome. Ann Surg Oncol; 2007 Feb;14(2):306-16
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphadenectomy for adenocarcinoma of the gastroesophageal junction (GEJ): impact of adequate staging on outcome.
  • INTRODUCTION: Adequate staging of gastric cancer requires examination of at least 15 lymph nodes.
  • METHODS: A prospectively maintained database identified 366 patients with Siewert types II and III adenocarcinoma of the GEJ who underwent R0 resection without neoadjuvant therapy at a single institution.
  • Multivariable analysis of adequately staged patients found the number of positive lymph nodes, T stage, and lymphovascular invasion to be independent prognostic factors for overall survival (OS).
  • For inadequately staged patients only the number of positive lymph nodes and T stage were independent prognostic factors.
  • [MeSH-major] Adenocarcinoma / pathology. Esophageal Neoplasms / pathology. Esophagogastric Junction. Lymph Node Excision / standards. Lymph Nodes / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17091329.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Mlkvý P: Multimodal therapy of gastric cancer. Dig Dis; 2010;28(4-5):615-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodal therapy of gastric cancer.
  • Adenocarcinoma of the stomach is the 2nd most common cancer worldwide.
  • The 5-year survival rates after curative surgical resection decline from 60-90% in stage I, to 30-50% in stage II and finally drop to only to 10-25% for patients in stage III of this disease.
  • According to certain criteria, early gastric cancer limited to the mucosa or submucosa is indicated for endoscopic mucosal resection.
  • In advanced gastric cancer with surgical approach, the questions of type of resection, extent of lymph node dissection and indication for splenectomy do arise.
  • Chemotherapy is the treatment of choice in stage IV for unresectable disease.
  • Survival rates in resectable gastric cancer are influenced mainly by the depth of invasion through the gastric wall and by the presence or absence of regional lymph node involvement.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 S. Karger AG, Basel.
  • (PMID = 21088412.001).
  • [ISSN] 1421-9875
  • [Journal-full-title] Digestive diseases (Basel, Switzerland)
  • [ISO-abbreviation] Dig Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


57. Garrido M, Bustos M, Orellana E, Madrid J, Galindo H, Sánchez C, Pimentel F, Guzmán S, Ibáñez L, Butte JM, Alvarez M, Besa P: [Postoperative radio-chemotherapy in locally advanced gastric cancer]. Rev Med Chil; 2008 Jul;136(7):844-50
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Postoperative radio-chemotherapy in locally advanced gastric cancer].
  • BACKGROUND: Overall 5 years survival for surgically excised gastric cancer is 30%.
  • AIM: To assess treatment results and toxicity in patients with surgically excised gastric cancer, treated with adjuvant radiotherapy and concomitant continuous 5-Fluorouracil (5-FU).
  • MATERIAL AND METHODS: Forty one patients aged 32 to 73 years (29 males) with stage II-IVA gastric cancer, subjected to a total or subtotal gastrectomy and D2 nodal dissection between 1997 to 2006, were studied.
  • They received adjuvant radiotherapy to the gastric bed and draining nodes in a total dose of 50.4 Gy in 28 fractions and chemotherapy with continuous infusion 5-FU, 200 mg/m(2)/day.
  • RESULTS: Eighteen patients were in stage II, 10 in stage IIIA, nine in stage IIIB and four in stage IVA.
  • CONCLUSIONS: Adjuvant radio-chemotherapy improved overall survival in gastric cancer, compared to historical controls subjected only to surgical treatment.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18949159.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Chile
  • [Chemical-registry-number] U3P01618RT / Fluorouracil
  •  go-up   go-down


58. Ishikawa M, Kitayama J, Kazama S, Hiramatsu T, Hatano K, Nagawa H: Plasma adiponectin and gastric cancer. Clin Cancer Res; 2005 Jan 15;11(2 Pt 1):466-72
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma adiponectin and gastric cancer.
  • BACKGROUND: Recently, increased body weight has been associated with an increased risk of cancers at multiple specific sites, including gastric cancer.
  • METHODS: Fasting plasma levels of adiponectin were determined in 75 patients with gastric cancer and 52 healthy controls using an ELISA.
  • In these patients, we analyzed the association between plasma adiponectin level and gastric cancer risk as well as various clinicopathologic characteristics.
  • RESULTS: Plasma adiponectin level was significantly lower in patients with gastric cancer than in healthy controls (9.1 +/- 6.2 versus 13.3 +/- 9.4 ng/mL, P < 0.01) and showed a significant modest inverse relation with the gastric cancer (odds ratio, 0.92; 95% confidence interval, 0.85-0.97; adjusted odds ratio, 0.89; 95% confidence interval, 0.84-0.95], although body mass index was not different.
  • In addition, adiponectin level was extremely low in patients with upper gastric cancers (upper, 5.5 +/- 4.1 ng/mL; middle, 9.7 +/- 6.4 ng/mL; lower, 10.7 +/- 4.1 ng/mL; P = 0.012).
  • Furthermore, adiponectin level tended to decrease as the tumor stage increased (stage I, 9.9 +/- 6.9 ng/mL; stage II, 8.7 +/- 5.5 ng/mL; stage III, 8.6 +/- 4.1 ng/mL; stage IV, 5.2 +/- 6.2 ng/mL; P = 0.34).
  • Interestingly, in 32 patients with undifferentiated cancer, serum adiponectin showed a negative correlation with pathologic findings such as tumor size, depth of invasion, as well as tumor stage (P < 0.05), but no correlation in the remaining 43 patients with differentiated cancer.
  • CONCLUSIONS: Our results suggest that a low plasma adiponectin level is associated with an increased risk for gastric cancer and raise the possibility that adiponectin has a potential role in the progression of gastric cancer, especially in undifferentiated type cancers in the upper stomach.
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / etiology. Adiponectin. Body Mass Index. Carcinoma, Signet Ring Cell / blood. Carcinoma, Signet Ring Cell / etiology. Case-Control Studies. Cell Differentiation. Collagen / blood. Down-Regulation. Fasting. Female. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Stomach / metabolism. Stomach / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15701829.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / R01 AG 21418; United States / NCI NIH HHS / CA / R01 CA 1018447; United States / NIDDK NIH HHS / DK / T32 DK 07790
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adiponectin; 0 / Intercellular Signaling Peptides and Proteins; 9007-34-5 / Collagen
  •  go-up   go-down


59. Ito S, Kodera Y, Mochizuki Y, Kojima T, Nakanishi H, Yamamura Y: Phase II clinical trial of postoperative S-1 monotherapy for gastric cancer patients with free intraperitoneal cancer cells detected by real-time RT-PCR. World J Surg; 2010 Sep;34(9):2083-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II clinical trial of postoperative S-1 monotherapy for gastric cancer patients with free intraperitoneal cancer cells detected by real-time RT-PCR.
  • BACKGROUND: We have previously reported the molecular detection of peritoneal micrometastases in patients with gastric cancer by quantifying carcinoembryonic antigen (CEA) mRNA in the peritoneal washes.
  • METHODS: CEA mRNA (+) patients with gastric cancer were treated postoperatively with S-1 monotherapy.
  • Overall survival, the primary endpoint of this phase II trial, was compared with the historical control, which is comprised of CEA mRNA (+) patients who were not given postoperative chemotherapy.
  • RESULTS: A total of 32 patients with CEA mRNA (+) gastric cancer were enrolled.
  • CONCLUSIONS: S-1 monotherapy, which significantly reduced risk for recurrence in stage II/III gastric carcinoma in another phase III trial, seems not to be as effective in eradicating free cancer cells in the abdominal cavity.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / administration & dosage. Oxonic Acid / administration & dosage. Peritoneal Neoplasms / secondary. Stomach Neoplasms / drug therapy. Stomach Neoplasms / mortality. Tegafur / administration & dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] World J Surg. 2011 Feb;35(2):468-9; author reply 470-1 [20857104.001]
  • [Cites] J Am Coll Surg. 2006 Feb;202(2):231-6 [16427547.001]
  • [Cites] Hepatogastroenterology. 2007 Apr-May;54(75):960-3 [17591103.001]
  • [Cites] Gastric Cancer. 2008;11(4):206-13 [19132482.001]
  • [Cites] Gastric Cancer. 2006;9(4):308-14 [17235634.001]
  • [Cites] Ann Surg Oncol. 2007 May;14 (5):1694-702 [17294072.001]
  • [Cites] Jpn J Cancer Res. 1997 Jul;88(7):687-92 [9310142.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Int J Cancer. 2000 Sep 20;89(5):411-7 [11008202.001]
  • [Cites] Clin Cancer Res. 1997 May;3(5):653-9 [9815733.001]
  • [Cites] Langenbecks Arch Surg. 2005 Sep;390(5):430-41 [15991048.001]
  • [Cites] Gastric Cancer. 2004;7(2):104-9 [15224197.001]
  • [Cites] Int J Oncol. 2005 Sep;27(3):637-44 [16077911.001]
  • [Cites] Jpn J Clin Oncol. 2005 Nov;35(11):672-5 [16275676.001]
  • [Cites] Br J Surg. 1990 Apr;77(4):436-9 [2340396.001]
  • [Cites] Anticancer Drugs. 1996 Jul;7(5):548-57 [8862723.001]
  • [Cites] Lancet Oncol. 2003 May;4(5):277-83 [12732164.001]
  • [Cites] Br J Cancer. 2005 Oct 31;93(9):986-92 [16205696.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;43 Suppl:S32-6 [10357556.001]
  • [Cites] Gynecol Oncol. 2001 Sep;82(3):581-9 [11520161.001]
  • [Cites] Oncology. 2000 Apr;58(3):191-7 [10765119.001]
  • [Cites] N Engl J Med. 2007 Nov 1;357(18):1810-20 [17978289.001]
  • [Cites] Eur J Cancer. 1998 Oct;34(11):1715-20 [9893658.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1441-7 [8336183.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):361-8 [16428473.001]
  • [Cites] Eur J Surg Oncol. 2009 Nov;35(11):1158-63 [19328643.001]
  • [Cites] Int J Cancer. 1998 Aug 21;79(4):429-33 [9699538.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14(9):2609-16 [18451223.001]
  • [Cites] Ann Surg. 2002 Apr;235(4):499-506 [11923605.001]
  • (PMID = 20379713.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Carcinoembryonic Antigen; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


60. Blackshaw G, Lewis WG, Hopper AN, Morgan MA, Al-Khyatt W, Edwards P, Roberts SA: Prospective comparison of endosonography, computed tomography, and histopathological stage of junctional oesophagogastric cancer. Clin Radiol; 2008 Oct;63(10):1092-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective comparison of endosonography, computed tomography, and histopathological stage of junctional oesophagogastric cancer.
  • AIMS: To assess the strength of agreement between the perceived preoperative stage of Siewert II (oesophagogastric junction) and Siewert III (proximal gastric tumours) as determined by computed tomography (CT) and endoscopic ultrasound (EUS), both alone and in combination, with histopathological stage.
  • METHODS: Forty-four patients with Siewert II (n=18) and III (n=26) adenocarcinomas of the oesophagogastric junction underwent preoperative CT at their local hospitals followed by specialist EUS, and the strengths of the agreement between the radiological stages and the histopathological stages were determined by the weighted Kappa statistic (Kw).
  • RESULTS: Kw for Siewert II T and N stages was 0.491 (p=0.016) and 0.4 (p=0.087) for CT compared with 0.852 (p=0.0001) and 1 (p=0.0001) for EUS.
  • CONCLUSION: Siewert II tumour T and N stages were more accurately predicted by EUS than CT, but Siewert III tumour T and N stages were more difficult to assess, arguably because of anatomical constraints at the oesophagogastric junction.
  • [MeSH-major] Adenocarcinoma / pathology. Esophageal Neoplasms / pathology. Esophagogastric Junction. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18774355.001).
  • [ISSN] 1365-229X
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


61. Carboni F, Lepiane P, Santoro R, Mancini P, Lorusso R, Santoro E: Laparoscopic surgery for gastric cancer: preliminary experience. Gastric Cancer; 2005;8(2):75-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic surgery for gastric cancer: preliminary experience.
  • BACKGROUND: Laparoscopic surgery for gastric cancer (GC) was introduced in the past decade because it was considered less invasive than open surgery, resulting in less postoperative pain, faster recovery, and improved quality of life.
  • METHODS: From November 2003 to December 2004, 20 patients affected by gastric adenocarcinoma were operated on with a totally laparoscopic or laparoscopic-assisted approach.
  • Procedures consisted of eight total gastrectomies, three subtotal Billroth I and seven Billroth II gastrectomies, one proximal gastrectomy, and one wedge resection.
  • According to the TNM classification, we observed five patients at stage Ia, four at stage Ib, three at stage II, one at stage IIIa, two at stage IIIb, and five at stage IV.
  • [MeSH-major] Adenocarcinoma / surgery. Laparoscopy / methods. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15864713.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


62. Xu DZ, Zhan YQ, Wu QL, Lai YR, Li W, Chen YB, Sun XW, Xu L, Guan YX, Li YF: [Infiltration length of gastric cancer on giant sections]. Ai Zheng; 2005 Jun;24(6):707-10
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Infiltration length of gastric cancer on giant sections].
  • BACKGROUND & OBJECTIVE: The resection boundary for gastric cancer is controversial.
  • The study was designed to investigate gastric wall infiltration length of gastric cancer.
  • METHODS: A total of 105 patients with gastric cancer who underwent gastrectomy at Cancer Center of Sun Yat-sen University from Apr.
  • During gastrectomy, gastric wall lengths of 18 patients before traction (L1), after traction (L2), and after isolation (L3) were measured.
  • Longitudinal specimen along the center of gastric cancer was fixed to measure the lengths of proximal and distal margins to the cancer.
  • The infiltration length of localized gastric cancer, including early stage cancer, Borrmann I type cancer, and Borrmann II type cancer, was less than 2 cmû that of invasive gastric cancer, including Borrmann III type cancer and Borrmann IV type cancer, was less than 5 cm.
  • CONCLUSION: The resection length for localized gastric cancer is at least 2 cm to tumor margin, and for invasive gastric cancer is at least 5 cm to tumor margin.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Gastrectomy / methods. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15946484.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


63. Moenig SP, Luebke T, Baldus SE, Schroeder W, Bollschweiler E, Schneider PM, Hoelscher AH: Feasibility of sentinel node concept in gastric carcinoma: clinicopathological analysis of gastric cancer with solitary lymph node metastases. Anticancer Res; 2005 Mar-Apr;25(2B):1349-52
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility of sentinel node concept in gastric carcinoma: clinicopathological analysis of gastric cancer with solitary lymph node metastases.
  • BACKGROUND: The feasibility and diagnostic reliability of sentinel lymph node biopsy of gastric carcinoma are still unclear and controversial.
  • PATIENTS AND METHODS: To assess the applicability of the sentinel node concept to gastric carcinoma, we retrospectively analyzed the location of metastatic lymph nodes in patients with only one or two lymph node metastases.
  • RESULTS: A total of 135 patients, who underwent gastrectomy with D2 lymphadenectomy for primary gastric adenocarcinoma between 1997 and 2001, were enrolled in this study.
  • Skip metastases were only seen in one patient with cardia carcinoma and lymph node involvement of compartment II (left gastric artery).
  • CONCLUSION: In patients with gastric carcinoma, especially in early stage carcinoma, the phenomenon of skip metastasis is infrequent.
  • Therefore, the sentinel node concept may be feasible in gastric cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15865090.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


64. Zhao L, Shen ZX, Luo HS, Yu JP: Clinical investigation on coexisting of duodenal ulcer and gastric cancer in China. Int J Clin Pract; 2005 Oct;59(10):1153-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical investigation on coexisting of duodenal ulcer and gastric cancer in China.
  • The aim of this study was to investigate the prevalence of coexistent duodenal ulcer and gastric cancer in China, then to explore the features of clinical manifestations, endoscopy, pathology and possible pathogenesis.
  • 37 cases of coexistent duodenal ulcer and gastric cancer were found.
  • Duodenal ulcer was single in all cases with seven in A1 stage, three in A2 stage, one in H1 stage, one in H2 stage, seven in S1 stage and 18 in S2 stage.
  • 89.2% (33/37) of concurrent gastric cancer were in the corpus and antrum, with 78.1% (29/37) of them belonging to Bormann type II and 87.1% (27/37) being moderately differentiated adenocarcinoma.
  • The coexisting gastric cancer in patients with duodenal ulcer is infrequent but not rare.
  • Helicobacter pylori eradication is recommended in patients with duodenal ulcer to reduce the risk of contaminant gastric cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16178981.001).
  • [ISSN] 1368-5031
  • [Journal-full-title] International journal of clinical practice
  • [ISO-abbreviation] Int. J. Clin. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


65. Schiesser M, Schneider PM: Surgical strategies for adenocarcinoma of the esophagogastric junction. Recent Results Cancer Res; 2010;182:93-106
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical strategies for adenocarcinoma of the esophagogastric junction.
  • This chapter summarizes the surgical strategies for adenocarcinomas of the distal esophagus, gastric cardia, and subcardial gastric cancer invading the cardia+/-distal esophagus known as adenocarcinomas of the esophagogastric junction (AEG).
  • The different surgical approaches according to the tumor origin, localization, and tumor stage are addressed with particular attention to the extent and type of resection and appropriate lymphadenectomy (LAD).
  • While type I tumors benefit from a transthoracic en bloc esophagectomy including a two-field LAD, type II and III tumors can be treated by an extended total gastrectomy with a transhiatal resection of the distal esophagus and LAD of the lower mediastinum and the abdominal D2 compartment.
  • [MeSH-major] Adenocarcinoma / surgery. Esophageal Neoplasms / surgery. Esophagogastric Junction. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20676874.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  •  go-up   go-down


66. Zhan YQ, Sun XW, Li W, Chen YB, Xu L, Guan YX, Li YF, Xu DZ: [Multivariate prognostic analysis in gastric carcinoma patients after radical operation]. Ai Zheng; 2005 May;24(5):596-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multivariate prognostic analysis in gastric carcinoma patients after radical operation].
  • BACKGROUND & OBJECTIVE: Whether received radical operation is an important prognostic factor of gastric carcinoma.
  • This study was to investigate prognostic factors of gastric carcinoma.
  • METHODS: Clinical data of 405 patients with gastric carcinoma, received radical operation from Jan.
  • The 5-year survival rates of patients in pathologic TNM (pTNM) stage I, II, III, and IV were 75.6%, 58.7%, 28.0%, and 18.4%, respectively (P < 0.01).
  • Univariate analysis showed that perioperative chemotherapy, Borrmann type, tumor size, pathologic type, and pTNM stage were prognostic factors of gastric carcinoma.
  • Multivariate analysis showed that pTNM stage, tumor size, and perioperative chemotherapy were independent prognostic factors of gastric carcinoma.
  • CONCLUSIONS: pTNM stage, tumor size, and perioperative chemotherapy are the most significant factors influencing prognosis of gastric carcinoma patients after radical operation.
  • Perioperative chemotherapy contributes to enhance survival rate of gastric carcinoma patients.
  • [MeSH-major] Adenocarcinoma / surgery. Gastrectomy. Stomach Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Signet Ring Cell / drug therapy. Carcinoma, Signet Ring Cell / pathology. Carcinoma, Signet Ring Cell / surgery. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Life Tables. Male. Middle Aged. Neoplasm Staging. Perioperative Care. Prognosis. Proportional Hazards Models. Survival Rate

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15890105.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


67. Han FH, Zhan WH, Li YM, He YL, Peng JS, Ma JP, Wang Z, Chen ZX, Zheng ZQ, Wang JP, Huang YH, Dong WG: [Analysis of long-term results of radical gastrectomy combining splenectomy for gastric cancer]. Zhonghua Wai Ke Za Zhi; 2005 Sep 1;43(17):1114-7
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of long-term results of radical gastrectomy combining splenectomy for gastric cancer].
  • OBJECTIVE: To analyze the influence of radical excision combining splenectomy on prognosis of the patients with gastric cancer.
  • METHODS: Between June 1994 and March 2004, 692 patients were operated on for gastric cancer and registered into gastric cancer database.
  • Radical excision (D2, D3 or D4) combining splenectomy for gastric cancer was performed in 45 cases.
  • Clinicopathological factors affecting lymph node metastasis, patterns of lymph node metastasis, 5-year survival rate after radical excision combined with splenectomy for gastric cancer were compared.
  • It was significantly different between gastric adenocarcinoma in proximal and body of stomach and that in distal stomach, poor differentiation and adenocarcinoma anaplastic and well and moderately differentiation adenocarcinoma, Borrmann III and IV types and Borrmann I and II types, infiltrated depth in T(3) and T(4) and infiltrated depth in T(1) and T(2), clinical stages III and IV and clinical stages I and II.
  • The average and median survival time between radical gastrectomy only and radical gastrectomy combining splenectomy for gastric cancer at stage I and II patients were significantly different, but at stage III and IV patients not significantly different.
  • CONCLUSIONS: Spleen should be reserved for patients with gastric cancer at stage I and II, and radical excision combining splenectomy could only be performed at stage III and IV patients with cancer infiltrating body and tail of the pancreas, or lymph nodes metastasis in the splenic hilus.
  • Indication of radical excision combining splenectomy for gastric cancer must be further study to clarify its efficacy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16194307.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


68. Früh M, Ruhstaller T, Neuweiler J, Cerny T: Resection of skin metastases from gastric carcinoma with long-term follow-up: an unusual clinical presentation. Onkologie; 2005 Jan;28(1):38-40
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resection of skin metastases from gastric carcinoma with long-term follow-up: an unusual clinical presentation.
  • BACKGROUND: Skin metastases from gastric cancer are rare and generally occur at a very late stage in the course of the disease.
  • CASE REPORT: A 60-year-old patient with localized adenocarcinoma of the cardia (stage II) was primarily treated with extended total gastrectomy with transhiatal resection of the distal esophagus.
  • CONCLUSION: We report a long-term disease-free survival of a patient with isolated cutaneous metastases of a gastric cancer.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Skin Neoplasms / secondary. Skin Neoplasms / surgery. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15604627.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


69. Shiraishi N, Sato K, Yasuda K, Inomata M, Kitano S: Multivariate prognostic study on large gastric cancer. J Surg Oncol; 2007 Jul 1;96(1):14-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multivariate prognostic study on large gastric cancer.
  • BACKGROUND: Although many authors investigate the prognostic factors of gastric cancer, there are few comprehensive studies on the prognosis of patients with large gastric cancer.
  • The aim of this study was to clarify the prognostic factors of large gastric cancer using multivariate analysis.
  • METHODS: The study included 95 patients who underwent gastrectomy for gastric cancer measuring 10 cm or more in diameter.
  • The 5-year survival rate was influenced by the tumor size, gross type, serosal invasion, extragastric lymph node metastasis, liver metastasis, peritoneal dissemination, stage of disease (I, II vs. III, IV), resection margin, and operative curability (R0 vs. R1, R2).
  • CONCLUSION: In patients with large gastric cancer, independent prognostic factors were serosal invasion, extragastric lymph node metastasis, and liver metastasis.
  • [MeSH-major] Adenocarcinoma / mortality. Gastrectomy / mortality. Lymph Nodes / pathology. Stomach Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 Wiley-Liss, Inc.
  • (PMID = 17582596.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 31
  •  go-up   go-down


70. Wang W, Li YF, Sun XW, Chen YB, Li W, Xu DZ, Guan XX, Huang CY, Zhan YQ, Zhou ZW: Prognosis of 980 patients with gastric cancer after surgical resection. Chin J Cancer; 2010 Nov;29(11):923-30
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis of 980 patients with gastric cancer after surgical resection.
  • BACKGROUND AND OBJECTIVE: Although surgery is the only possible means to cure gastric cancer, the prognosis is often discrepant.
  • The American Joint Committee on Cancer / International Union against Cancer (AJCC/UICC) published the TNM classification of Malignant Tumors (seventh edition) for gastric cancer recently.
  • This study aimed to use this new edition staging system to investigate the prognostic factors for gastric cancer.
  • METHODS: The clinicopathologic data of 980 patients with gastric cancer treated by surgical resection in our hospital between January 2000 and December 2006 were analyzed retrospectively.
  • The 5-year survival rates for patients with pTNM stage I, II, III, and IV disease classified by the 7th edition staging system were 93.2%, 72.4%, 39.1%, and 5.2%, respectively.
  • CONCLUSION: Compared with the 6th edition system, the new edition of TNM staging system for gastric cancer can accurately predict the survival after operation.
  • [MeSH-major] Adenocarcinoma. Gastrectomy. Neoplasm Staging / standards. Stomach Neoplasms
  • [MeSH-minor] Adenocarcinoma, Mucinous / classification. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Signet Ring Cell / classification. Carcinoma, Signet Ring Cell / pathology. Carcinoma, Signet Ring Cell / surgery. Cohort Studies. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Proportional Hazards Models. Retrospective Studies. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20979691.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] China
  •  go-up   go-down


71. Aoyagi K, Kouhuji K, Yano S, Miyagi M, Imaizumi T, Takeda J, Shirouzu K: VEGF significance in peritoneal recurrence from gastric cancer. Gastric Cancer; 2005;8(3):155-63
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] VEGF significance in peritoneal recurrence from gastric cancer.
  • BACKGROUND: In gastric cancer, the management of peritoneal dissemination in the Peritoneal cavity is extremely important; however, peritoneal dissemination in the final stage of gastric cancer remains untreatable.
  • METHODS: Immunohistochemical staining, using the avidin-biotin peroxidase complex method, was performed on slides of surgical specimens from 40 patients with stage II gastric cancer with serosal invasion, who underwent surgery at our hospital between 1990 and 2000.
  • Of these, seven had macroscopic type-4 scirrhous-type gastric carcinoma.
  • CONCLUSION: These results suggested that VEGF was correlated with peritoneal metastasis from gastric cancer, and that VEGF was a useful indicator of peritoneal recurrence.
  • [MeSH-minor] Adenocarcinoma, Scirrhous / metabolism. Adenocarcinoma, Scirrhous / pathology. Adult. Aged. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Invasiveness / pathology. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1999 Jan 1;85(1):178-87 [9921991.001]
  • [Cites] Cancer Sci. 2003 Aug;94(8):735-40 [12901801.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):622-30 [10690548.001]
  • [Cites] J Biol Chem. 1998 Nov 13;273(46):30336-43 [9804796.001]
  • [Cites] Cancer Res. 1995 Jan 15;55(2):360-8 [7812969.001]
  • [Cites] J Natl Cancer Inst. 1998 Mar 18;90(6):447-54 [9521169.001]
  • [Cites] Int J Cancer. 1997 Mar 4;70(5):612-8 [9052764.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] Am J Pathol. 1998 Oct;153(4):1249-56 [9777956.001]
  • [Cites] J Exp Med. 1992 Oct 1;176(4):1165-74 [1383376.001]
  • [Cites] Am J Pathol. 1995 May;146(5):1029-39 [7538264.001]
  • [Cites] Jpn J Cancer Res. 1996 Dec;87(12):1235-44 [9045958.001]
  • [Cites] Science. 1983 Feb 25;219(4587):983-5 [6823562.001]
  • [Cites] Int Surg. 2003 Jan-Mar;88(1):25-33 [12731728.001]
  • [Cites] Ann Surg Oncol. 1999 Jun;6(4):373-8 [10379858.001]
  • [Cites] J Natl Cancer Inst. 1995 Apr 5;87(7):506-16 [7707437.001]
  • [Cites] J Biol Regul Homeost Agents. 2001 Apr-Jun;15(2):140-4 [11501971.001]
  • [Cites] Biochem Biophys Res Commun. 1991 Dec 16;181(2):902-6 [1755866.001]
  • [Cites] J Cell Physiol. 1992 Dec;153(3):557-62 [1447317.001]
  • [Cites] Gene Ther. 2000 Jun;7(12):1027-33 [10871751.001]
  • [Cites] Cancer Res. 1999 Nov 1;59(21):5412-6 [10554007.001]
  • (PMID = 16086118.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


72. Kolodziejczyk P, Kulig J, Popiela T, Sierzega M, Jedrys J, Czupryna A, Kubisz A, Szczepanik A, Klek S, Polish Gastric Cancer Study Group: Outcome of gastric cancer surgery in elderly patients. Hepatogastroenterology; 2005 Nov-Dec;52(66):1911-5
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of gastric cancer surgery in elderly patients.
  • BACKGROUND/AIMS: The aim of the study was to review cases of gastric cancers in elderly adults (70 years of age and older), and compare demographic, clinical, pathologic features and outcomes of surgical treatment with younger patients (below 70 years of age).
  • METHODOLOGY: The analysis included 3431 patients treated for gastric cancer between 1977 and 1998 at eight university surgical centers cooperating for the Polish Gastric Cancer Study Group (PGCSG).
  • Patients were analyzed retrospectively according to data obtained from standardized forms and divided into two groups: group I--patients 70 years of age and over, group II--younger patients.
  • The overall 5-year survival was 24% and 35% for group I and II, respectively (p<0.05), and increased to 35% and 53% after radical resections, respectively.
  • However, there were no statistically significant differences in stage-specific survival between both groups.
  • CONCLUSIONS: Surgical resection is the method of choice in the treatment of gastric cancer.
  • Age of the patients is not a contraindication to surgical treatment of gastric cancer.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Postoperative Complications / epidemiology. Stomach Neoplasms / mortality. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16334805.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


73. Zhao ZS, Wang YY, Ye ZY, Tao HQ: Prognostic value of tumor-related molecular expression in gastric carcinoma. Pathol Oncol Res; 2009 Dec;15(4):589-96
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of tumor-related molecular expression in gastric carcinoma.
  • In order to identify reliable molecular markers for prognostic prediction in gastric carcinoma, we evaluated the expression of six molecular markers, namely bFGF, IGF-2, HGF, MMP-9, integrin beta3 and uPA in gastric cancer.
  • There was a significant correlation between the expression of these markers and the depth of tumor invasion, vessel invasion, lymph node and distant metastasis, TNM stage and microvessel density.
  • Multivariate analysis showed that abnormal expression of bFGF, MMP-9 and uPA, as well as depth of invasion, lymph node and distant metastasis and TNM stage were independently related to poor prognosis of gastric cancer.
  • MMP-9, bFGF and uPA are potential candidates for development as clinically applicable molecular prognostic markers for gastric carcinoma, and may be effective therapeutic targets for the disease in the future.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Signet Ring Cell / diagnosis. Fibroblast Growth Factor 2 / metabolism. Matrix Metalloproteinase 9 / metabolism. Stomach Neoplasms / diagnosis. Urokinase-Type Plasminogen Activator / metabolism
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Disease Progression. Female. Gene Expression Regulation, Neoplastic. Hepatocyte Growth Factor / metabolism. Humans. Insulin-Like Growth Factor II / metabolism. Integrin beta3 / metabolism. Male. Middle Aged. Multivariate Analysis. Neovascularization, Pathologic. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cancer Ther. 2005 Sep;4(9):1399-408 [16170032.001]
  • [Cites] Eur J Cancer. 2001 Nov;37(17):2257-63 [11677116.001]
  • [Cites] Ann Surg Oncol. 2007 Oct;14(10):2738-47 [17687613.001]
  • [Cites] J Surg Oncol. 2006 Aug 1;94(2):149-54 [16847924.001]
  • [Cites] Postgrad Med J. 2005 Jul;81(957):419-24 [15998815.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 2005 Nov;27(11):676-9 [16438890.001]
  • [Cites] Pancreas. 2002 Aug;25(2):122-9 [12142733.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):921-32 [10679663.001]
  • [Cites] Clin Chim Acta. 2005 Apr;354(1-2):91-9 [15748604.001]
  • [Cites] J Korean Med Sci. 2006 Apr;21(2):272-8 [16614513.001]
  • [Cites] Mod Pathol. 2001 Nov;14(11):1126-32 [11706074.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):161-74 [11990853.001]
  • [Cites] J Cell Biochem. 2003 Jun 1;89(3):529-38 [12761886.001]
  • [Cites] Eur J Vasc Endovasc Surg. 2004 Jul;28(1):89-97 [15177237.001]
  • [Cites] Biochem Biophys Res Commun. 2008 May 16;369(4):1215-20 [18355442.001]
  • [Cites] Hepatogastroenterology. 2007 Jul-Aug;54(77):1591-5 [17708308.001]
  • [Cites] Hepatogastroenterology. 1999 Jan-Feb;46(25):568-73 [10228863.001]
  • [Cites] Neurosci Lett. 2007 Apr 24;417(1):1-5 [17386975.001]
  • [Cites] J Biol Chem. 1999 May 7;274(19):13066-76 [10224058.001]
  • [Cites] Eur J Cancer Prev. 2007 Dec;16(6):517-27 [18090124.001]
  • [Cites] Cancer Sci. 2003 Jan;94(1):43-9 [12708473.001]
  • [Cites] Exp Mol Med. 2005 Jun 30;37(3):213-9 [16000876.001]
  • [Cites] N Engl J Med. 1991 Jan 3;324(1):1-8 [1701519.001]
  • [Cites] World J Gastroenterol. 2003 May;9(5):899-904 [12717827.001]
  • (PMID = 19294533.001).
  • [ISSN] 1532-2807
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Integrin beta3; 103107-01-3 / Fibroblast Growth Factor 2; 67256-21-7 / Hepatocyte Growth Factor; 67763-97-7 / Insulin-Like Growth Factor II; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


74. Nakamura R, Saikawa Y, Wada N, Yoshida M, Kubota T, Kumai K, Kitajima M: Retrospective analysis of prognosis for scirrhous-type gastric cancer: one institution's experience. Int J Clin Oncol; 2007 Aug;12(4):291-4
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective analysis of prognosis for scirrhous-type gastric cancer: one institution's experience.
  • BACKGROUND: Scirrhous gastric cancer is biologically aggressive, and the prognosis is poor even with curative surgery.
  • METHODS: Records for 83 patients, who were treated between 1991 and 2004, were evaluated for survival and stage, treatment, and clinicopathological factors.
  • RESULTS: Cumulative 5-year overall survival was 10.2% for all 83 patients, including 27 (32.5%) patients with stage II/III disease and 56 (67.4%) with stage IV disease.
  • The 5-year overall survival rate and median survival time for patients with stage II/III disease after curative surgery were 24.3% and 1150 days.
  • For patients with stage IV disease, 2-year and 5-year survival rates after initial surgery were 13.7% and 0% and median survival was 250 days.
  • [MeSH-major] Adenocarcinoma, Scirrhous / therapy. Stomach Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 1997 Apr-May;4(3):209-14 [9142381.001]
  • [Cites] J Surg Oncol. 1995 Feb;58(2):112-7 [7844980.001]
  • [Cites] Surg Gynecol Obstet. 1992 Jul;175(1):13-6 [1621194.001]
  • [Cites] Oncol Rep. 2003 Mar-Apr;10(2):381-6 [12579276.001]
  • [Cites] Surgery. 1989 Oct;106(4):758-62; discussion 762-3 [2552599.001]
  • [Cites] J Surg Oncol. 1997 Jul;65(3):194-200 [9236929.001]
  • [Cites] Gastric Cancer. 1998 Dec;1(1):10-24 [11957040.001]
  • [Cites] Dig Dis Sci. 1992 May;37(5):757-63 [1563320.001]
  • [Cites] Hepatogastroenterology. 2005 Jan-Feb;52(61):314-8 [15783058.001]
  • [Cites] Br J Cancer. 2003 Dec 15;89(12):2207-12 [14676796.001]
  • [Cites] Am J Surg. 2004 Sep;188(3):327-32 [15450843.001]
  • [Cites] Gastric Cancer. 2003;6 Suppl 1:40-4 [12775019.001]
  • [Cites] Intern Med. 1996 Dec;35(12):930-6 [9030989.001]
  • (PMID = 17701009.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


75. Santoro R, Carboni F, Lepiane P, Ettorre GM, Santoro E: Clinicopathological features and prognosis of gastric cancer in young European adults. Br J Surg; 2007 Jun;94(6):737-42
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological features and prognosis of gastric cancer in young European adults.
  • BACKGROUND: The aims of this study were to define the clinicopathological features and prognosis of gastric cancer in young European adults.
  • METHODS: Between 1990 and 2004, 603 patients with gastric cancer were enrolled in a prospective database.
  • RESULTS: In the younger group there were significantly more women (57 versus 36.3 per cent; P = 0.004), Laurén diffuse-type carcinomas (73 versus 42.7 per cent; P < 0.001), N2-3 lymph node metastases (59 versus 38.9 per cent; P = 0.005), stage IV disease (49 versus 35.7 per cent; P = 0.085) and resections that were non-curative (36 versus 18.5 per cent; P = 0.007) than in the older patients.
  • Unfavourable prognostic factors associated with poor 5-year survival were the degree of gastric wall invasion (T3-4 versus T1-2; P < 0.001), lymph node invasion (positive versus negative; P < 0.001), disease stage (III-IV versus I-II; P < 0.001) and curability of resection (non-curative versus curative; P < 0.001).
  • CONCLUSION: Gastric cancer in young adults tends to be more advanced; however, when matched for stage, the prognosis does not differ from that of older patients.
  • [MeSH-major] Adenocarcinoma / pathology. Gastrectomy / methods. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 British Journal of Surgery Society Ltd.
  • (PMID = 17330827.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


76. Carrato A, Gallego-Plazas J, Guillen-Ponce C: Adjuvant therapy of resected gastric cancer is necessary. Semin Oncol; 2005 Dec;32(6 Suppl 9):S105-8
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant therapy of resected gastric cancer is necessary.
  • The currently reported 5-year survival rates for patients with resected stage II, IIIA, IIIB, and IV gastric cancer are 34%, 20%, 8%, and 7%, respectively.
  • Other agents in combination with perioperative radiotherapy and surgery are being investigated to treat patients with gastric cancer.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16399445.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] United States
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


77. Rojo F, Tabernero J, Albanell J, Van Cutsem E, Ohtsu A, Doi T, Koizumi W, Shirao K, Takiuchi H, Ramon y Cajal S, Baselga J: Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. J Clin Oncol; 2006 Sep 10;24(26):4309-16
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma.
  • PURPOSE: Epidermal growth factor receptor (EGFR) is highly expressed in some gastric cancers and is implicated in cancer cell growth and proliferation.
  • The objective of this study was to assess the in situ biologic activity of the EGFR tyrosine kinase inhibitor gefitinib in gastric tumor samples in a phase II study.
  • METHODS: Patients with previously treated stage IV adenocarcinoma of the stomach or gastroesophageal junction were randomly assigned to receive gefitinib (250 or 500 mg/d).
  • CONCLUSION: Gefitinib reached the tumors at concentrations sufficient to inhibit EGFR activation in advanced gastric carcinoma patients, although this did not translate into clinical benefit.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Oncol. 2006 Dec 10;24(35):5620. Ramon Cajal, S [corrected to Ramon y Cajal, S]
  • (PMID = 16963731.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases; S65743JHBS / gefitinib
  •  go-up   go-down


78. Dalal KM, Woo Y, Kelly K, Galanis C, Gonen M, Fong Y, Coit DG: Detection of micrometastases in peritoneal washings of gastric cancer patients by the reverse transcriptase polymerase chain reaction. Gastric Cancer; 2008;11(4):206-13
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of micrometastases in peritoneal washings of gastric cancer patients by the reverse transcriptase polymerase chain reaction.
  • BACKGROUND: Gastric cancer patients with positive (+) peritoneal cytology have a prognosis similar to stage IV patients.
  • METHODS: Peritoneal washings were obtained prospectively from 34 patients with gastric adenocarcinoma undergoing staging laparoscopy and 6 patients undergoing laparoscopy for benign disease.
  • RESULTS: Pathologic stages for the gastric cancer patients were: stage I, 9 (27%); stage II, 7 (21%); stage III, 15 (44%); and stage IV, 3 (9%).
  • The four cytology (+) patients were: stage II, 1; stage III, 1; and stage IV, 2.
  • [MeSH-major] Adenocarcinoma / secondary. Peritoneal Cavity / pathology. Peritoneal Neoplasms / secondary. Reverse Transcriptase Polymerase Chain Reaction. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 2006 Feb;202(2):231-6 [16427547.001]
  • [Cites] Ann Surg Oncol. 2007 May;14 (5):1694-702 [17294072.001]
  • [Cites] Int J Cancer. 2006 Oct 15;119(8):1850-7 [16721789.001]
  • [Cites] Br J Obstet Gynaecol. 1989 May;96(5):574-9 [2604772.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):678-85 [12576435.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jan 23;313(4):931-7 [14706632.001]
  • [Cites] Cancer. 1978 Sep;42(3 Suppl):1412-8 [361200.001]
  • [Cites] Ann Surg Oncol. 2005 May;12(5):347-53 [15915368.001]
  • [Cites] Br J Surg. 2004 Apr;91(4):435-43 [15048743.001]
  • [Cites] Can J Otolaryngol. 1975;4(1):46-50 [1131725.001]
  • [Cites] Clin Chem. 1993 Apr;39(4):561-77 [8472349.001]
  • [Cites] J Gastrointest Surg. 2007 Dec;11(12):1598-605; discussion 1605-6 [17879123.001]
  • [Cites] Gastric Cancer. 2005;8(3):142-8 [16086116.001]
  • [Cites] Chin Med J (Engl). 2004 Aug;117(8):1210-7 [15361297.001]
  • [Cites] Clin Cancer Res. 1999 Dec;5(12):4158-63 [10632355.001]
  • [Cites] J Gastrointest Surg. 1998 May-Jun;2(3):244-9 [9841981.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):365-72 [17146744.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10):3406-11 [9779720.001]
  • [Cites] J Cancer Res Clin Oncol. 1984;108(2):236-8 [6470030.001]
  • [Cites] Cancer Res. 2001 Dec 15;61(24):8664-7 [11751382.001]
  • [Cites] Am J Dig Dis. 1978 Feb;23(2):129-33 [623075.001]
  • [Cites] Ann Surg Oncol. 2007 Oct;14(10):2702-13 [17653801.001]
  • [Cites] Semin Nucl Med. 1975 Jul;5(3):255-62 [1154032.001]
  • [Cites] Br J Surg. 2000 Feb;87(2):236-42 [10671934.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Surg Oncol. 1999 Oct;72(2):60-4; discussion 64-5 [10518099.001]
  • [Cites] J Surg Oncol. 1995 Aug;59(4):226-9 [7630168.001]
  • [Cites] Br J Surg. 1996 May;83(5):672-4 [8689216.001]
  • [Cites] J Clin Endocrinol Metab. 1981 Mar;52(3):457-62 [6893991.001]
  • [Cites] Int J Cancer. 1998 Aug 21;79(4):429-33 [9699538.001]
  • [Cites] Ann Surg. 2002 Apr;235(4):499-506 [11923605.001]
  • (PMID = 19132482.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Inhibitor of Apoptosis Proteins; 0 / Keratin-20; 0 / MUC2 protein, human; 0 / Microtubule-Associated Proteins; 0 / Mucin-2; 0 / RNA, Messenger
  •  go-up   go-down


79. Nitti D, Marchet A, Mocellin S, Rossi GM, Ambrosi A, Mencarelli R: Prognostic value of subclassification of T2 tumours in patients with gastric cancer. Br J Surg; 2009 Apr;96(4):398-404
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of subclassification of T2 tumours in patients with gastric cancer.
  • BACKGROUND: This study was designed to evaluate the prognostic value of tumour stage T2 subcategorization (T2a and T2b) in patients with gastric carcinoma.
  • METHODS: Clinicopathological details of a prospective series of patients who had radical resection of gastric adenocarcinoma in a single institution were analysed.
  • On multivariable analysis, T stage remained an independent prognostic factor.
  • CONCLUSION: Subclassification of T2 tumours should be undertaken routinely in order to stratify patients with gastric cancer more accurately in terms of their mortality risk.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
  • (PMID = 19283740.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


80. Ott K, Lordick F, Herrmann K, Krause BJ, Schuhmacher C, Siewert JR: The new credo: induction chemotherapy in locally advanced gastric cancer: consequences for surgical strategies. Gastric Cancer; 2008;11(1):1-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The new credo: induction chemotherapy in locally advanced gastric cancer: consequences for surgical strategies.
  • Perioperative chemotherapy in stage II and stage III gastric cancer is now accepted as a standard of care in the Western world.
  • The MUNICON (Metabolic response evalUatioN for Individualisation of neoadjuvant Chemotherapy in oesOphageal and oesophagogastric adeNocarcinoma) I study confirmed prospectively the usefulness of early metabolic response evaluation and showed the feasibility of a PET-guided treatment algorithm.
  • In gastric cancer, we have analyzed FDG-PET in a prospective study.
  • In gastric cancer the issue is more complicated, because about 30% of gastric cancers cannot be visualized with sufficient contrast for quantification.
  • Insufficient FDG uptake is mostly associated with diffuse-type gastric cancer with signet ring cells and mucinous content.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1999 Mar 25;340(12):908-14 [10089184.001]
  • [Cites] Cancer. 2005 Dec 1;104(11):2365-72 [16245310.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Ann Surg. 2007 Oct;246(4):624-8; discussion 628-31 [17893499.001]
  • [Cites] J Clin Oncol. 1999 Aug;17 (8):2403-11 [10561303.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Feb;33(2):148-55 [16228236.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1521-30 [14508841.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):279-86 [11466680.001]
  • [Cites] Radiology. 2006 May;239(2):472-80 [16543584.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12 ):3058-65 [11408502.001]
  • [Cites] J Nucl Med. 2005 Dec;46(12 ):2029-34 [16330567.001]
  • [Cites] Ann Surg. 1999 Mar;229(3):303-8 [10077040.001]
  • [Cites] Cancer. 1993 Oct 1;72(7):2089-97 [8374867.001]
  • [Cites] Lancet Oncol. 2007 Sep;8(9):797-805 [17693134.001]
  • [Cites] Gastric Cancer. 2003;6(3):159-67 [14520529.001]
  • [Cites] Surg Oncol Clin N Am. 2000 Jan;9(1):97-117, vii-viii [10601527.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4692-8 [16966684.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):2307-15 [12796400.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2069-77 [15082726.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4604-10 [14673049.001]
  • [Cites] J Nucl Med. 2005 Oct;46(10 ):1582-8 [16204706.001]
  • [Cites] Ann Surg. 2005 May;241(5):810-7; discussion 817-20 [15849517.001]
  • [Cites] Jpn J Clin Oncol. 2003 Oct;33(10):533-7 [14623923.001]
  • [Cites] Gastric Cancer. 2000 Dec 27;3(3):128-133 [11984725.001]
  • [Cites] Zhonghua Wai Ke Za Zhi. 2006 May 15;44(10 ):661-4 [16784672.001]
  • [Cites] Nucl Med Commun. 2004 Aug;25(8):825-31 [15266178.001]
  • [Cites] World J Surg. 2004 Mar;28(3):247-53 [14961197.001]
  • [Cites] Gastric Cancer. 2006;9(3):192-6 [16952037.001]
  • [Cites] Ann Thorac Surg. 2004 Oct;78(4):1152-60; discussion 1152-60 [15464463.001]
  • [Cites] Cancer. 2005 Jun 1;103(11):2383-90 [15856477.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Gan To Kagaku Ryoho. 2000 Dec;27(14):2179-84 [11142160.001]
  • [Cites] Cancer. 1994 Jun 1;73(11):2680-6 [8194005.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 Feb;59(3):313-20 [16770582.001]
  • [Cites] Cancer. 2001 Mar 1;91(5):918-27 [11251943.001]
  • [Cites] Ann Surg Oncol. 2001 Jul;8(6):519-24 [11456051.001]
  • [Cites] Br J Cancer. 2006 May 8;94(9):1281-6 [16622464.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Feb;30(2):288-95 [12552348.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • (PMID = 18373171.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Contrast Media; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 42
  •  go-up   go-down


81. Kutun S, Celik A, Cem Kockar M, Erkorkmaz U, Eroğlu A, Cetin A, Erkosar B, Yakicier C: Expression of CK-19 and CEA mRNA in peripheral blood of gastric cancer patients. Exp Oncol; 2010 Dec;32(4):263-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of CK-19 and CEA mRNA in peripheral blood of gastric cancer patients.
  • AIM: To investigate the clinical and pathological relevance of detection of circulating tumor cells (CTC) in the peripheral blood of gastric carcinoma patients before operation.
  • PATIENTS AND METHODS: Fifty patients with gastric adenocarcinoma were analysed prospectively.
  • Group I (unresectable) consisted of 22, and group II (resectable) consisted of 28 patients.
  • Tumor localisation, stage, presence of signet cell formation, nodal metastases, serousal and lymphovascular invasion were recorded for all patients.
  • Nine patients (40%) in group I and 15 (53.6%) in group II were positive for CK-19 expression.
  • The median 1 and 2-year survival was 9.5 and 10.5 months for group I, and 20 and 28.5 months for group II, respectively (p = 0.001).
  • It can be suggested that expression of both CEA and CK-19 in the peripheral blood of gastric cancer patients are strong predictors of MVI and significantly worse survival rates.
  • [MeSH-major] Adenocarcinoma / blood. Biomarkers, Tumor / blood. Carcinoembryonic Antigen / blood. Keratin-19 / blood. Neoplastic Cells, Circulating / metabolism. Stomach Neoplasms / blood

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21270756.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Keratin-19; 0 / RNA, Messenger
  •  go-up   go-down


82. Griniatsos J, Gakiopoulou H, Yiannakopoulou E, Dimitriou N, Douridas G, Nonni A, Liakakos T, Felekouras E: Routine modified D2 lymphadenectomy performance in pT1-T2N0 gastric cancer. World J Gastroenterol; 2009 Nov 28;15(44):5568-72
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Routine modified D2 lymphadenectomy performance in pT1-T2N0 gastric cancer.
  • AIM: To evaluate routine modified D2 lymphadenectomy in gastric cancer, based on immunohistochemically detected skip micrometastases in level II lymph nodes.
  • METHODS: Among 95 gastric cancer patients who were routinely submitted to curative modified D2 lymphadenectomy, from January 2004 to December 2008, 32 were classified as pN0.
  • The level II lymph nodes of the remaining 28 patients were studied immunohistochemically for micrometastases detection and constitute the material of the present study.
  • RESULTS: Skip micrometastases in the level II lymph nodes were detected in 14% (4 out of 28) of the patients.
  • The incidence was further increased to 17% (4 out of 24) in the subgroup of T1-2 gastric cancer patients.
  • Thus, the disease was upstaged from stage IA to IB in one patient and from stage IB to II in three patients.
  • CONCLUSION: In gastric cancer, true R0 resection may not be achieved without modified D2 lymphadenectomy.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Lymph Node Excision / methods. Lymphatic Metastasis / diagnosis. Stomach Neoplasms / diagnosis. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Oncol Clin N Am. 2001 Oct;10(4):833-54, ix [11641094.001]
  • [Cites] Ann Surg Oncol. 2009 Mar;16(3):609-13 [19137375.001]
  • [Cites] Gastric Cancer. 2002;5(1):1-5 [12021853.001]
  • [Cites] Cancer. 2002 Jun 1;94(11):2867-73 [12115374.001]
  • [Cites] Anticancer Res. 2003 Jan-Feb;23(1B):601-4 [12680154.001]
  • [Cites] World J Surg. 2003 May;27(5):558-61 [12715223.001]
  • [Cites] Melanoma Res. 2003 Jun;13(3):313-24 [12777989.001]
  • [Cites] Eur J Surg Oncol. 2004 Apr;30(3):303-8 [15028313.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2069-77 [15082726.001]
  • [Cites] Cochrane Database Syst Rev. 2004;(4):CD001964 [15495024.001]
  • [Cites] Acta Cytol. 1992 Mar-Apr;36(2):241-5 [1371897.001]
  • [Cites] Lancet. 1995 Mar 25;345(8952):745-8 [7891484.001]
  • [Cites] Lancet. 1996 Apr 13;347(9007):995-9 [8606613.001]
  • [Cites] J Clin Oncol. 1996 Aug;14(8):2289-94 [8708719.001]
  • [Cites] Cancer. 1997 Oct 15;80(8):1393-8 [9338462.001]
  • [Cites] N Engl J Med. 1999 Mar 25;340(12):908-14 [10089184.001]
  • [Cites] Ann Thorac Surg. 2005 Jan;79(1):225-33 [15620948.001]
  • [Cites] Gastric Cancer. 2005;8(2):64-70 [15864711.001]
  • [Cites] J Surg Oncol. 2005 Jun 1;90(3):153-65 [15895448.001]
  • [Cites] ANZ J Surg. 2005 Aug;75(8):645-9 [16076325.001]
  • [Cites] Am J Surg Pathol. 2005 Sep;29(9):1135-44 [16096401.001]
  • [Cites] World J Gastroenterol. 2005 Oct 14;11(38):5920-5 [16273600.001]
  • [Cites] Ann Surg. 2006 Mar;243(3):341-7 [16495698.001]
  • [Cites] Gastric Cancer. 2006;9(3):197-202 [16952038.001]
  • [Cites] Cancer. 2006 Nov 1;107(9):2143-51 [17001662.001]
  • [Cites] Hepatogastroenterology. 2007 Jan-Feb;54(73):81-4 [17419236.001]
  • [Cites] Gastric Cancer. 2007;10(2):87-91 [17577617.001]
  • [Cites] Ann Surg Oncol. 2007 Jul;14(7):2028-35 [17453300.001]
  • [Cites] J Surg Oncol. 2007 Jul 1;96(1):14-8 [17582596.001]
  • [Cites] Jpn J Clin Oncol. 2007 Jun;37(6):429-33 [17656480.001]
  • [Cites] Ann Surg Oncol. 2007 Sep;14(9):2432-4 [17520315.001]
  • [Cites] J Surg Oncol. 2008 Feb 1;97(2):125-30 [18095267.001]
  • [Cites] J Gastrointest Surg. 2008 Mar;12(3):550-4 [17786527.001]
  • [Cites] Ann Surg Oncol. 2008 Mar;15(3):770-6 [18157577.001]
  • [Cites] Surg Oncol. 2008 Sep;17(3):203-10 [18539025.001]
  • [Cites] J Natl Cancer Inst. 2008 Nov 19;100(22):1574-80 [19001602.001]
  • [Cites] Ann Surg Oncol. 2009 Mar;16(3):603-8 [19127361.001]
  • [Cites] Jpn J Clin Oncol. 2001 Oct;31(10):495-9 [11696619.001]
  • (PMID = 19938196.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2785060
  •  go-up   go-down


83. Bazas VM, Lukyanova NY, Lisovenko GS, Rozumiy DO, Potebnya GP: Postoperative autovaccinotherapy for patients with gastric cancer and expression of some proteins in tumor tissue. Exp Oncol; 2009 Sep;31(3):182-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative autovaccinotherapy for patients with gastric cancer and expression of some proteins in tumor tissue.
  • AIM: To study the efficacy of autovaccine in the treatment of gastric cancer and significance of molecular factors having prognostic values for disease outcome to evaluate its efficacy in clinical setting.
  • PATIENTS AND METHODS: 150 patients with histologically proven adenocarcinoma of the stomach of stages II, III or IV were enrolled into study.
  • RESULTS: It was shown that application of AV has resulted in the increase of 3-year overall survival of patients having stage III of disease by more than 30%, but those having stage IV - only around 14%.
  • Gastric cancer patients with p53, EGFR, HER-2/neu, beta-catenin, VEGF and Bcl-2-positive tumors are the favorable group for the treatment with AV in the adjuvant regime.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / therapy. Female. Humans. Immunoenzyme Techniques. Lymphatic Metastasis. Male. Neoplasm Staging. Postoperative Care. Prognosis. Proto-Oncogene Proteins c-bcl-2 / metabolism. Receptor, Epidermal Growth Factor / metabolism. Receptor, ErbB-2 / metabolism. Survival Rate. Tumor Suppressor Protein p53 / metabolism. Vaccination. Vascular Endothelial Growth Factor A / metabolism. beta Catenin / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19783961.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Autovaccines; 0 / Biomarkers, Tumor; 0 / CTNNB1 protein, human; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 0 / beta Catenin; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


84. Wydmański J, Suwiński R, Miszczyk L, Maka B, Maciejewski B: [Evaluation of tolerance and efficacy of postoperative combined radiotherapy and chemotherapy in locally advanced gastric cancer]. Przegl Lek; 2005;62(12):1431-5
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of tolerance and efficacy of postoperative combined radiotherapy and chemotherapy in locally advanced gastric cancer].
  • PURPOSE: To assess the toxicity and the efficacy of adjuvant radio-chemotherapy in patients with high-risk gastric cancer.
  • METHODS AND MATERIALS: Patients with adenocarcinoma of the stomach were enrolled into the study from April 1999 to December 2000.
  • Three year survival rates in stage II, III and IV were 67%, 24% and 17% respectively.
  • CONCLUSION: Postoperative radio-chemotherapy in patients with locally advanced gastric cancer was safe and well tolerated.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiography. Stomach Neoplasms / drug therapy. Stomach Neoplasms / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16786766.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


85. Al-Taie OH, Adam P, Kraus MR, Illert B, Scheurlen M: Giant fold gastritis with consecutive gastric carcinoma in a patient with peutz-jeghers syndrome. Z Gastroenterol; 2005 Jul;43(7):653-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant fold gastritis with consecutive gastric carcinoma in a patient with peutz-jeghers syndrome.
  • We describe the case of a 36-year-old patient with Peutz-Jeghers syndrome and a very unusual gastric morphology resembling giant fold gastritis.
  • Endoscopic ultrasound documented a hyperechoic widening of the gastric mucosa without involvement of the deeper layers.
  • However, despite annual control gastroscopies, an adenocarcinoma developed between the folds and was in an already advanced stage at diagnosis (UICC III).
  • [MeSH-major] Adenocarcinoma / diagnosis. Gastritis, Hypertrophic / diagnosis. Peutz-Jeghers Syndrome / diagnosis. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Adult. Cell Transformation, Neoplastic / pathology. Endosonography. Gastrectomy. Gastric Mucosa / pathology. Gastric Mucosa / surgery. Gastroscopy. Helicobacter Infections / diagnosis. Helicobacter Infections / pathology. Helicobacter pylori. Humans. Male. Neoplasm Staging. Predictive Value of Tests

  • Genetic Alliance. consumer health - Peutz Jeghers syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16001347.001).
  • [ISSN] 0044-2771
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


86. Chen JS, Rau KM, Chen YY, Huang JS, Yang TS, Lin YC, Liau CT, Lee KD, Su YC, Kao RH: A multiple-center phase II study of biweekly oxaliplatin and tegafur-uracil/leucovorin for chemonaive patients with advanced gastric cancer. Cancer Chemother Pharmacol; 2009 Apr;63(5):819-25
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multiple-center phase II study of biweekly oxaliplatin and tegafur-uracil/leucovorin for chemonaive patients with advanced gastric cancer.
  • PURPOSE: The current study assessed the efficacy and safety of biweekly oxaliplatin combining oral tegafur-uracil/leucovorin in treating chemonaive patients with advanced gastric cancer.
  • METHODS: Eligible patients were 18-75 years old, had stage IV disease or post-surgery recurrence, no prior palliative chemotherapy, and an ECOG performance status of 0-2.
  • CONCLUSIONS: Biweekly, oxaliplatin combining oral tegafur-uracil/leucovorin in treating patients with advanced gastric cancer showed acceptable activity and manageable toxicity.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18663448.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; Q573I9DVLP / Leucovorin
  •  go-up   go-down


87. Fang WL, Wu CW, Lo SS, Chen JH, Hsieh MC, Shen KH, Li AF, Tai LC, Lui WY: Mucin-producing gastric cancer: clinicopathological difference between signet ring cell carcinoma and mucinous carcinoma. Hepatogastroenterology; 2009 Jul-Aug;56(93):1227-31
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucin-producing gastric cancer: clinicopathological difference between signet ring cell carcinoma and mucinous carcinoma.
  • BACKGROUND/AIMS: Signet ring cell carcinoma and mucinous carcinoma are mucin-producing gastric cancers.
  • METHODOLOGY: From December 1987 to July 2005, a total of 1612 gastric cancer patients received curative surgery, 128 patients with signet ring cell carcinoma and 48 with mucinous carcinoma were enrolled in this study.
  • RESULTS: Early stage (stage I and II) patients with mucinous carcinoma were associated with more male predominant (p = 0.002), larger tumor size (p = 0.020), deeper cancer invasion (p < 0.001), and a worse 5-year overall survival (63.6% vs 88.2%, p = 0.012) than those with signet ring cell carcinoma.
  • There was no significant difference between the two groups with advanced stage in 5-year overall survival.
  • CONCLUSIONS: Patients with mucinous carcinoma had different biological behaviors with those with signet ring cell carcinoma, in particular early stage, hence had a worse survival.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Signet Ring Cell / pathology. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19760976.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


88. Brenner B, Shah MA, Karpeh MS, Gonen M, Brennan MF, Coit DG, Klimstra DS, Tang LH, Kelsen DP: A phase II trial of neoadjuvant cisplatin-fluorouracil followed by postoperative intraperitoneal floxuridine-leucovorin in patients with locally advanced gastric cancer. Ann Oncol; 2006 Sep;17(9):1404-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of neoadjuvant cisplatin-fluorouracil followed by postoperative intraperitoneal floxuridine-leucovorin in patients with locally advanced gastric cancer.
  • BACKGROUND: The aim of the study was to evaluate the efficacy and toxicity of neoadjuvant chemotherapy with intravenous (i.v.) cisplatin and fluorouracil (5-FU), surgery and postoperative intraperitoneal (i.p.) floxuridine (FUdR) and leucovorin (LV) in patients with locally advanced gastric cancer.
  • T stage downstaging (pretreatment LAP versus surgical pathological stage) was seen in 23% of patients.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLOXURIDINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16788003.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA56225
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 039LU44I5M / Floxuridine; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


89. Ott K, Lordick F: [Neoadjuvant therapy in the upper gastro-intestinal tract. Gastric cancer from a surgical viewpoint]. Chirurg; 2009 Nov;80(11):1028-34
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neoadjuvant therapy in the upper gastro-intestinal tract. Gastric cancer from a surgical viewpoint].
  • The prognosis of locally advanced gastric cancer remains poor.
  • Two randomized studies that have been performed in Europe have shown that peri-operative chemotherapy significantly improves the survival of patients with adenocarcinoma of the stomach and of the gastro-esophageal junction.
  • These results have a profound effect on the treatment of patients presenting with stage II or stage III disease.
  • Neither mortality nor complication rate are increased after neoadjuvant chemotherapy for gastric cancer.
  • Patients with locally advanced gastric cancer should always be referred to experienced high volume centers, where the findings are discussed in a multidisciplinary tumor board.
  • [MeSH-major] Adenocarcinoma / surgery. Esophagogastric Junction. Neoadjuvant Therapy. Stomach Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3719-25 [17704421.001]
  • [Cites] N Engl J Med. 1999 Mar 25;340(12):908-14 [10089184.001]
  • [Cites] Int J Cancer. 2006 Dec 15;119(12):2885-94 [16929515.001]
  • [Cites] Lancet Oncol. 2006 Apr;7(4):309-15 [16574546.001]
  • [Cites] Clin Cancer Res. 2008 Apr 1;14 (7):2012-8 [18381939.001]
  • [Cites] Chirurg. 2006 Nov;77(11):971-80 [17066269.001]
  • [Cites] Chirurg. 2007 Sep;78(9):792-801 [17676284.001]
  • [Cites] Gastric Cancer. 2005;8(1):1-5 [15747167.001]
  • [Cites] Ann Surg Oncol. 2009 Apr;16(4):1017-25 [19189186.001]
  • [Cites] Ann Surg. 2007 Jul;246(1):1-8 [17592282.001]
  • [Cites] Chirurg. 2006 Mar;77(3):227-35 [16511688.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1521-30 [14508841.001]
  • [Cites] Radiology. 2006 May;239(2):472-80 [16543584.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5095-102 [17785563.001]
  • [Cites] Ann Surg. 1999 Mar;229(3):303-8 [10077040.001]
  • [Cites] Lancet Oncol. 2007 Sep;8(9):797-805 [17693134.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4692-8 [16966684.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):2307-15 [12796400.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2069-77 [15082726.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4604-10 [14673049.001]
  • [Cites] Ann Surg. 2004 Nov;240(5):808-16 [15492562.001]
  • [Cites] N Engl J Med. 2008 Jul 31;359(5):453-62 [18669424.001]
  • [Cites] Gastric Cancer. 2008;11(1):1-9 [18373171.001]
  • [Cites] Lancet Oncol. 2006 Aug;7(8):644-51 [16887481.001]
  • [Cites] N Engl J Med. 2007 Nov 1;357(18):1810-20 [17978289.001]
  • [Cites] J Am Coll Surg. 2007 Oct;205(4):593-601 [17903735.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] Chirurg. 1999 May;70(5):520-9 [10412596.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • (PMID = 19756431.001).
  • [ISSN] 1433-0385
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 30
  •  go-up   go-down


90. Pan Y, Liang H, Xue Q, Zhang RP, Cui QH, Liu N, Wang BG: [Comparison of the prognostic value of UICC and JGCA lymph node staging criteria for gastric cancer]. Zhonghua Zhong Liu Za Zhi; 2008 May;30(5):376-80
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison of the prognostic value of UICC and JGCA lymph node staging criteria for gastric cancer].
  • OBJECTIVE: To compare the correlation of prognosis with UICC or JGCA lymph node staging criteria for gastric cancer and evaluate the value of application of those two TNM staging systems in prognosis prediction.
  • METHODS: From January 1996 to December 2005, 395 gastric cancer patients who underwent D2 or D2 plus radical gastrectomy with > or = 15 lymph nodes removed were enrolled into this study.
  • No significant difference was found in the 5-year survival rates of stage I , II, III and IV based on either UICC or JGCA TNM staging criteria.
  • CONCLUSION: Our results show that UICC staging system is more predictive and relevant to prognosis than JGCA staging system for gastric cancer, and D2 or D2 plus radical gastrectomy with at least or more than 15 lymph nodes removed is required when UICC-TNM gastric cancer staging criteria is applied.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / pathology. Lymph Nodes / pathology. Neoplasm Staging / methods. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18953840.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


91. Han FH, Zhan WH, Li YM, He YL, Peng JS, Cai SR, Ma JP, Wang Z: [Analyses of surgical treatment and prognosis in gastric stump cancer]. Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Jan;12(1):28-31
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analyses of surgical treatment and prognosis in gastric stump cancer].
  • OBJECTIVE: To evaluate the efficacy of surgical treatment and the prognosis in gastric stump cancer patients.
  • METHODS: Between June 1994 and March 2004, 692 patients underwent radical operation for gastric cancer in our department.
  • Among them, 22 cases were gastric stump cancer.
  • RESULTS: Gastric stump cancer accounted for 3.2 % of all the gastric cancer cases in the same period.
  • There were 4 cases of stage I, 2 cases of stage II, 6 cases of stage III and 10 cases of stage IIII respectively.
  • Radical gastric stump cancer excisions were finished with abdominal incision in 18 cases and with thoraco-abdominal incision in 4 cases.
  • Average survival time was(80.2+/-17.2) months in stage I( and II( gastric remnant cancer; average survival time was(31.2+/-9.2) months in stage III( gastric remnant cancer, average survival time was (23.6+/-6.1) months in stage IIII( gastric remnant cancer, which were significantly different(all P<0.05).
  • Between palliative operation group and standard radical excision, extended radical excision groups, well-moderate differentiated and poor differentiated adenocarcinoma groups, lymph node metastasis positive and negative groups, the differences were all significant.
  • CONCLUSIONS: Total gastrectomy and D(2) lymph node dissection are imperative for radical excision of gastric remnant cancer.
  • Tumor stage, procedure pattern, lymph node metastasis and tumor differentiation affect the prognosis of patients with gastric stump cancer.
  • [MeSH-major] Gastric Stump / pathology. Gastric Stump / surgery. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19145499.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


92. Guo HJ, Wang X, Liu YC, Wan YL, Yin HF, Li T, Zhu J: [Expression of proline-rich tyrosine kinase-2 (Pyk2) in gastric carcinoma and its significance]. Beijing Da Xue Xue Bao; 2005 Jun 18;37(3):261-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of proline-rich tyrosine kinase-2 (Pyk2) in gastric carcinoma and its significance].
  • OBJECTIVE: To investigate whether proline-rich tyrosine kinase-2 (Pyk2) is expressed differently in normal gastric mucosas and gastric carcinoma tissues and further to evaluate its significance.
  • METHODS: Expressions of Pyk2 in 59 cases of normal gastric mucosas and 52 cases of gastric carcinoma tissues were analysed by immunohistochemical methods.
  • RESULTS: Immunohistochemical studies showed that the positive rates of Pyk2 protein expression in normal gastric mucosas and gastric carcinoma tissues were 86.44% (51/59) and 19.23% (10/52) respectively.
  • The difference between normal gastric mucosas and gastric carcinoma tissues was statistically significant (P<0.05).
  • The positive rates of Pyk2 expression in highly differentiated gastric carcinoma and moderately/lowly differentiated gastric carcinoma were 47.37% (9/19) and 3.03% (1/33) respectively.
  • Statistically significant differences (P<0.05) were observed in the levels of Pyk2 expression between highly differentiated gastric carcinoma and moderately/lowly differentiated gastric carcinoma.
  • The positive rates of Pyk2 expression at different TNM stages gastric carcinoma were respectively: stage I 66.67% (6/9), stage II 30% (3/10), stage III 3.45% (1/29), stage IV 0% (0/4).
  • The differences were statistically significant [(II+III+IV) v I, chi2=15.767, P<0.05].
  • CONCLUSION: In this study, we demonstrate that Pyk2 is expressed in normal gastric mucosas, whereas its expression declines significantly or almost disappears in gastric carcinoma tissues.
  • The expression of Pyk2 progressively decreases with increasing grade of malignancy and TNM stages of gastric carcinoma.
  • This phenomenon indicates that Pyk2 expression may be involved in the generation and development of gastric carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Focal Adhesion Kinase 2 / biosynthesis. Stomach Neoplasms / metabolism
  • [MeSH-minor] Gastric Mucosa / metabolism. Humans. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15968315.001).
  • [ISSN] 1671-167X
  • [Journal-full-title] Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  • [ISO-abbreviation] Beijing Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.10.2 / Focal Adhesion Kinase 2
  •  go-up   go-down


93. Di Martino N, Izzo G, Cosenza A, Vicenzo L, Monaco L, Torelli F, Basciotti A, Brillantino A, Marra A: [Total gastrectomy for gastric cancer: can the type of lymphadenectomy condition the long-term results?]. Suppl Tumori; 2005 May-Jun;4(3):S84-5
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Total gastrectomy for gastric cancer: can the type of lymphadenectomy condition the long-term results?].
  • INTRODUCTION: Gastric cancer is the second tumor for frequency in the world.
  • Indeed lymphonodal metastasis seem to be one of the most important prognostic factors in the gastric cancer and the level and the number of metastatic nodes are useful to predict the patients' survival.
  • The aim of this study is to value the D2 lymphadenectomy in the patients who were treated with total gastrectomy for gastric adenocarcinoma, comparing the results both with the D1 lymphadenectomy and the D3-D4, paying attention to the survival rates related with the lymphonodal dissection.
  • PATIENTS AND METHOD: From 1998 to 2004, we studied 87 patients with gastric cancer.
  • We followed the Japanese Research Society for Gastric Cancer guidelines, according to which nodes are gathered into 16 levels and divided in 4 groups (N1-N4) depending on the cancer localization.
  • The 5 years survival for the Ia stage was 82.6%, 89.3% for the Ib stage, 67.8% for the II stage, 56.6% for the IIIa, 16.8% for the IIIb and 0% for the IV stage.
  • CONCLUSIONS: The relation between long distance survival and extension of the lymphadenectomy in the patients with gastric adenocarcinoma is still being discussed.
  • Different studies show the importance of a careful lymphadenectomy as the main mean for a better long distance survival in the patients with gastric cancer.
  • Other studies showed a link between gastric cancer prognosis and number of positive nodes.
  • Therefore the presence of nod metastasis has a negative influence in the prognosis of this tumor; for this reason D2 lymphadenectomy is the technique to be used for the treatment of the gastric adenocarcinoma, both for a good staging and a better long distance survival, but particularly in the advanced cancers which are, at the moment, the highest number of cases that reach the surgeon's attention.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437920.001).
  • [ISSN] 2283-5423
  • [Journal-full-title] I supplementi di Tumori : official journal of Società italiana di cancerologia ... [et al.]
  • [ISO-abbreviation] Suppl Tumori
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


94. Zhang XL, Yang YS, Xu DP, Qu JH, Guo MZ, Gong Y, Huang J: Comparative study on overexpression of HER2/neu and HER3 in gastric cancer. World J Surg; 2009 Oct;33(10):2112-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative study on overexpression of HER2/neu and HER3 in gastric cancer.
  • Recent evidence that HER3 is responsible for tumor resistance to therapeutic agents targeting EGFR or HER2/neu, along with the new findings that HER3 is involved in the process of dedifferentiation of gastric cancer (GC) have highlighted the critical role of HER3 in cancer research.
  • Here, we comparatively investigated the expression of HER2/neu and HER3 in gastric cancer of two pathologic types (intestinal type and diffuse type) using immunohistochemistry (IHC) and analyzed the correlation between overexpression of HER2 and HER3 and clinicopathologic parameters.
  • The overexpression rates of HER2 and HER3 in phase III-IV (TNM stage) disease were significantly higher than that in phase I-II disease (24.0% vs. 7.7%, p < 0.05 and 22.0% vs. 5.8%, p < 0.05, respectively).
  • CONCLUSIONS: The selective overexpression of HER2 and HER3 in the two histologic types of gastric cancer is strongly associated with a poor prognosis.
  • Being an important member of the HER family, HER3 may become another candidate for molecular-targeted therapy in gastric cancer, especially for the diffuse histologic type.
  • [MeSH-major] Adenocarcinoma / metabolism. Receptor, Epidermal Growth Factor / biosynthesis. Receptor, ErbB-2 / biosynthesis. Stomach Neoplasms / metabolism


95. Hasegawa S, Yoshikawa T, Cho H, Tsuburaya A, Kobayashi O: Is adenocarcinoma of the esophagogastric junction different between Japan and western countries? The incidence and clinicopathological features at a Japanese high-volume cancer center. World J Surg; 2009 Jan;33(1):95-103
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is adenocarcinoma of the esophagogastric junction different between Japan and western countries? The incidence and clinicopathological features at a Japanese high-volume cancer center.
  • BACKGROUND: We clarified the incidence of adenocarcinoma of the esophagogastric junction (AEG) at a Japanese high-volume cancer center and its clinicopathological features between the Siewert subtypes.
  • METHODS: Patients with AEG were selected from a prospective database of gastric and esophageal tumors established by Kanagawa Cancer Center.
  • RESULTS: From January 1986 to December 2005, 147 (4.0%) patients were determined to have AEG; 2,794 (75.8%) were diagnosed to be true gastric cancer, whereas 745 (20.2%) were true esophageal cancer.
  • Of these 147 patients with AEG, 5 (3.4%) were classified as type I, 82 (55.8%) as type II, and 60 (40.8%) as type III tumors.
  • The depth of tumor invasion was deeper and the nodal metastases were more frequent in type III compared with type II.
  • The pathological grade was higher in type III than in type II.
  • Although the 5-year survival rate was significantly higher in type II than in type III tumors, the survival difference disappeared when the patients were restricted to an R0 resection, even though type III patients demonstrated a more advanced stage.
  • [MeSH-major] Adenocarcinoma / pathology. Esophageal Neoplasms / pathology. Esophagogastric Junction / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Thorac Surg. 2002 Apr;73(4):1035-40 [11996237.001]
  • [Cites] Br J Cancer. 1990 Sep;62(3):440-3 [2206952.001]
  • [Cites] J Surg Oncol. 2005 Jun 1;90(3):139-46; discussion 146 [15895452.001]
  • [Cites] Cancer. 2000 Dec 15;89(12):2555-9 [11135215.001]
  • [Cites] N Engl J Med. 2002 Nov 21;347(21):1662-9 [12444180.001]
  • [Cites] Ann Surg Oncol. 2006 Jan;13(1):12-30 [16378161.001]
  • [Cites] World J Surg. 2003 Mar;27(3):334-8 [12607062.001]
  • [Cites] Gastric Cancer. 1998 Dec;1(1):10-24 [11957040.001]
  • [Cites] Surgery. 1998 Feb;123(2):127-30 [9481396.001]
  • [Cites] Lancet Oncol. 2006 Aug;7(8):644-51 [16887481.001]
  • [Cites] World J Surg. 2006 Mar;30(3):364-71 [16485063.001]
  • [Cites] Arch Surg. 1994 Apr;129(4):381-8; discussion 388-9 [7512326.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] J Am Coll Surg. 1999 Dec;189(6):594-601 [10589596.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] Surgery. 1998 Oct;124(4):707-13; discussion 713-4 [9780992.001]
  • (PMID = 18958523.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Sakakibara T, Hibi K, Koike M, Fujiwara M, Kodera Y, Ito K, Nakao A: PAI-1 expression levels in gastric cancers are closely correlated to those in corresponding normal tissues. Hepatogastroenterology; 2008 Jul-Aug;55(85):1480-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PAI-1 expression levels in gastric cancers are closely correlated to those in corresponding normal tissues.
  • BACKGROUND/AIMS: To investigate the mechanism of PAI-1 overexpression in gastric cancers, the PAI-1 expression levels in gastric cancers were compared to those in the corresponding normal tissues.
  • METHODOLOGY: A quantitative RT-PCR for PAI-1 gene was performed in gastric cancers and corresponding normal tissues, and evaluated the association between the PAI-1 expression levels in gastric cancers and those in corresponding normal tissues.
  • RESULTS: There was a significant correlation between gastric cancer and corresponding normal PAI-1 expressions with a Spearman's rank correlation coefficient of 0.74 (p < 0.0001).
  • PAI-1 expression levels in corresponding normal tissues increased significantly with tumor stage [stage I, -8.04 +/- 0.72; stage II, -7.71 +/- 0.61: stage III, -6.81 +/- 0.51; stage IV, -4.95 +/- 0.20 (p = 0.0022)).
  • CONCLUSIONS: Previous studies found that PAI-1 overexpression was significantly associated with malignancy of gastric cancers.
  • Taken together, PAI-1 overexpression in gastric cancers might be originated from higher PAI-1 expression in corresponding normal tissues and result in a malignant phenotype of these cancers.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Plasminogen Activator Inhibitor 1 / metabolism. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18795717.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Plasminogen Activator Inhibitor 1; 0 / RNA, Messenger; 0 / SERPINE1 protein, human
  •  go-up   go-down


97. Jang YJ, Park MS, Park SS, Kim JH, An H, Park SH, Kim SJ, Kim CS, Mok YJ: Surgeon subspecialty as a factor in improving long-term outcomes for gastric cancer: Twenty years of experience in Korea. Arch Surg; 2010 Nov;145(11):1091-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgeon subspecialty as a factor in improving long-term outcomes for gastric cancer: Twenty years of experience in Korea.
  • BACKGROUND: The results of gastric cancer treatment have improved during the past 2 decades.
  • This study analyzed data accumulated during the past 20 years regarding the impact of surgical subspecialty on gastric cancer prognosis.
  • PATIENTS: A total of 2797 patients admitted between 1984 and 2003 with surgically treated, pathologically confirmed, primary gastric adenocarcinoma.
  • A Cox proportional hazards regression model showed that age, sex, tumor location, type of resection, stage, and the interaction between period of study and surgical subspecialty were independent prognostic factors.
  • CONCLUSIONS: This large, long-term cohort study demonstrates that the management of gastric cancer has been largely successful, with favorable trends in prognostic factors.
  • Successful outcomes are realized more often by gastric surgical specialists.
  • Efforts must be made to improve the treatment of patients with stage II gastric cancer because the improvements in long-term results have plateaued.
  • [MeSH-major] Adenocarcinoma / surgery. Clinical Competence. Gastrectomy / methods. Specialties, Surgical. Stomach Neoplasms / surgery. Workload

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Surg. 2010 Nov;145(11):1096-7 [21121098.001]
  • (PMID = 21079098.001).
  • [ISSN] 1538-3644
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


98. Madani K, Zhao R, Lim HJ, Casson AG: Prognostic value of p53 mutations in oesophageal adenocarcinoma: final results of a 15-year prospective study. Eur J Cardiothorac Surg; 2010 Jun;37(6):1427-32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of p53 mutations in oesophageal adenocarcinoma: final results of a 15-year prospective study.
  • OBJECTIVE: This study evaluates the clinical significance of p53 mutations in oesophageal adenocarcinoma (EADC).
  • Strict clinicopathologic criteria were used to define primary EADC (Type I), excluding gastric cardia adenocarcinoma (Type II).
  • Conventional predictors of reduced OS included advanced pathological tumour-node-metastasis (pTNM) stage (P<0.0001) and number of involved lymph nodes (0, 1-3, >3; P<0.0001).
  • [MeSH-major] Adenocarcinoma / genetics. Esophageal Neoplasms / genetics. Genes, p53. Mutation

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20227286.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


99. Harada K, Noguchi T, Fujiwara S, Moriyama H, Kitano S, Kawahara K: [Complete response in an elderly patient with advanced gastric cancer treated with TS-1]. Gan To Kagaku Ryoho; 2007 Mar;34(3):427-30
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Complete response in an elderly patient with advanced gastric cancer treated with TS-1].
  • He was diagnosed with advanced gastric cancer, T2N1H0P0M0, stage II.
  • From now on, as society grays more and more, it is considered that elderly advanced gastric cancer patients with complications will increase.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Oxonic Acid / therapeutic use. Stomach Neoplasms / drug therapy. Tegafur / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17353636.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


100. Kassam Z, Lockwood G, O'brien C, Brierley J, Swallow C, Oza A, Siu L, Knox JJ, Wong R, Cummings B, Kim J, Moore M, Ringash J: Conformal radiotherapy in the adjuvant treatment of gastric cancer: Review of 82 cases. Int J Radiat Oncol Biol Phys; 2006 Jul 1;65(3):713-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conformal radiotherapy in the adjuvant treatment of gastric cancer: Review of 82 cases.
  • BACKGROUND: The Intergroup 0116 study showed a survival benefit with adjuvant chemoradiotherapy (CRT) for resected gastric cancer.
  • METHODS AND MATERIALS: Eighty-two patients with resected gastric or gastroesophageal junction (GEJ) adenocarcinoma, Stage IB to IV (M0), were treated with 45 Gy in 25 fractions using a 5-field conformal technique.
  • Chemotherapy was in accordance with the Intergroup 0116 study, or infusional 5-fluorouracil and cisplatin in a phase I/II trial.
  • CONCLUSION: Adjuvant CRT for gastric cancer, even with conformal RT, is associated with significant toxicity.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Radiotherapy, Conformal. Stomach Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16626887.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down






Advertisement